<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9015098</article-id><article-id pub-id-type="pmcid-ver">PMC9015098.1</article-id><article-id pub-id-type="pmcaid">9015098</article-id><article-id pub-id-type="pmcaiid">9015098</article-id><article-id pub-id-type="pmid">35444961</article-id><article-id pub-id-type="doi">10.3389/fcimb.2022.869039</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With <italic toggle="yes">Onchocerca ochengi</italic>
</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhan</surname><given-names initials="B">Bin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/468572"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bottazzi</surname><given-names initials="ME">Maria Elena</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1432694"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hotez</surname><given-names initials="PJ">Peter J.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1432843"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lustigman</surname><given-names initials="S">Sara</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/568591"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Texas Children&#8217;s Hospital Center for Vaccine Development, Baylor College of Medicine</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Laboratory of Molecular Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Mohammad M. Pourseif, Tabriz University of Medical Sciences, Iran</p></fn><fn fn-type="edited-by"><p>Reviewed by: Peter Geldhof, Ghent University, Belgium; Stephen Ghogomu, University of Buea, Cameroon</p></fn><corresp id="fn001">*Correspondence: Bin Zhan, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:bzhan@bcm.edu">bzhan@bcm.edu</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">400318</issue-id><elocation-id>869039</elocation-id><history><date date-type="received"><day>03</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>07</day><month>3</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>19</day><month>04</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-25 16:25:14.883"><day>25</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Zhan, Bottazzi, Hotez and Lustigman</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Zhan, Bottazzi, Hotez and Lustigman</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcimb-12-869039.pdf"/><abstract><p>Human onchocerciasis is a devastating neglected tropical disease caused by infection of the filarial nematode <italic toggle="yes">Onchocerca volvulus</italic>. The infection can cause irreversible visual impairment or blindness and stigmatizing dermatitis. More than 32 million people were estimated to be infected with <italic toggle="yes">O. volvulus</italic> in Africa, and 385,000 suffered from blindness. Even though the implementation of mass drug administration (MDA) with ivermectin has reduced the global prevalence of onchocerciasis, <italic toggle="yes">O. volvulus</italic> infection remains challenging to control because MDA with ivermectin cannot be implemented in endemic areas co-endemic with loiasis due to the risk of severe adverse events. There is also emerging drug resistance to ivermectin that further complicates the elimination of onchocerciasis. Thus, the development of a vaccine that would induce protective immunity and reduce infection burden is essential. Efforts to develop prophylactic and/or therapeutic vaccines for onchocerciasis have been explored since the late 1980s by many researchers and entities, and here we summarize the recent advances made in the development of vaccines against the infection of <italic toggle="yes">O. volvulus</italic> and onchocerciasis.</p></abstract><kwd-group><kwd><italic toggle="yes">Onchocerca volvulus</italic></kwd><kwd>onchocerciasis</kwd><kwd>vaccine</kwd><kwd>animal model</kwd><kwd>clinical trial</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>National Institute of Allergy and Infectious Diseases
</institution><institution-id institution-id-type="doi">10.13039/100000060</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="135"/><page-count count="17"/><word-count count="10082"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Human onchocerciasis or river blindness is a serious parasitic disease caused by infection of the filarial nematode <italic toggle="yes">Onchocerca volvulus</italic> transmitted through the bite of an infected blackfly (<xref rid="B80" ref-type="bibr">Lustigman, 2018</xref>). It is a devastating neglected tropical disease with an adverse impact on human health and socioeconomic status because it causes irreversible visual impairment or blindness and stigmatizing dermatitis (<xref rid="B104" ref-type="bibr">Schwartz et&#160;al., 2020</xref>). Some evidence indicates that onchocerciasis may also cause seizures and epilepsy (<xref rid="B100" ref-type="bibr">Romo, 2020</xref>). More than 32 million people were estimated to be infected with <italic toggle="yes">O. volvulus</italic>, most of whom live in sub-Saharan Africa, before the mass drug administration (MDA) with ivermectin was initiated in 1995 (<xref rid="B22" ref-type="bibr">Coffeng et&#160;al., 2013</xref>). Approximately 385,000 suffered from blindness, 944,000 from low vision, and 3 million from severe itching (<xref rid="B127" ref-type="bibr">WHO, 2010</xref>). Even though the implementation of MDA with ivermectin and vector control results in a significant reduction in the global prevalence of onchocerciasis, it remains highly prevalent. Recent estimates from the Global Burden of Disease Study 2019 indicate that 19.1 million people live with onchocerciasis with the highest prevalence and disease burdens in the Democratic Republic of the Congo and neighboring Central African Republic, South Sudan, Chad, and Cameroon (<xref rid="B60" ref-type="bibr">Institute for Health Metrics and Evaluation</xref>). In these endemic areas on the African continent, onchocerciasis results in an estimated 1.23 million years lost from disability due to debilitating effects of skin disease and vision impairment (<xref rid="B44" ref-type="bibr">G. B. D. Disease Injury Incidence and Prevalence Collaborators, 2018</xref>). In 2019, more than 200 million people in 30 countries required preventive therapy for onchocerciasis (<xref rid="B128" ref-type="bibr">WHO, 2020</xref>).</p><p>MDA using ivermectin alone may not be sufficient to achieve onchocerciasis elimination due to several key barriers. First, MDA with ivermectin cannot be implemented in areas co-endemic with onchocerciasis and loiasis due to the risk of severe adverse events (SAEs) including encephalopathy in patients infected with filarial <italic toggle="yes">Loa loa</italic> treated with ivermectin (<xref rid="B43" ref-type="bibr">Gardon et&#160;al., 1997</xref>; <xref rid="B73" ref-type="bibr">Kelly-Hope et&#160;al., 2014</xref>). Failure to control onchocerciasis in these regions allows the establishment of reservoirs of <italic toggle="yes">Onchocerca</italic> infection to spread into neighboring areas that previously received MDA (<xref rid="B73" ref-type="bibr">Kelly-Hope et&#160;al., 2014</xref>). Another concern for ivermectin MDA is the emergence and/or potential widespread of partial or complete ivermectin drug-resistant <italic toggle="yes">O. volvulus</italic>, which may reduce the long-term effectiveness of ivermectin when used alone in the endemic regions (<xref rid="B87" ref-type="bibr">Lustigman and McCarter, 2007</xref>; <xref rid="B116" ref-type="bibr">Turner et&#160;al., 2013</xref>). Based on these limitations, a disease modeling study concluded that it may not be possible to eliminate onchocerciasis even after 50 years of annual ivermectin MDA; this has prompted suggestions to adopt a biannual treatment program to reach the goal of the London Declaration on Neglected Tropical Diseases Goals for onchocerciasis (<xref rid="B23" ref-type="bibr">Dadzie et&#160;al., 2003</xref>; <xref rid="B117" ref-type="bibr">Turner et&#160;al., 2014</xref>).</p><p>Based on these limitations, the development of new tools such as new drugs and vaccines will be necessary to ensure sustainable onchocerciasis elimination (<xref rid="B59" ref-type="bibr">Hotez et&#160;al., 2015</xref>; <xref rid="B80" ref-type="bibr">Lustigman, 2018</xref>), as proposed in the WHO, 2021&#8211;2030 Roadmap on Neglected Tropical Diseases (<xref rid="B129" ref-type="bibr">WHO, 2021</xref>). The development of prophylactic and therapeutic vaccines will complement current and future chemotherapeutic programs and thus accelerate the elimination efforts of onchocerciasis worldwide (<xref rid="B59" ref-type="bibr">Hotez et&#160;al., 2015</xref>; <xref rid="B91" ref-type="bibr">Makepeace et&#160;al., 2015</xref>). The efforts to develop prophylactic and/or therapeutic vaccines for onchocerciasis have been explored since the late 1980s by many researchers and entities, and here we summarize the recent advances made in the development of vaccines against the infection <italic toggle="yes">of O. volvulus</italic> and onchocerciasis.</p></sec><sec id="s2"><title>Animal Models</title><p>A major obstacle for vaccine development against <italic toggle="yes">O. volvulus</italic> infection was the lack of a suitable animal model used to evaluate the immunogenicity and vaccine efficacy of human vaccines. The <italic toggle="yes">O. volvulus</italic> parasite only naturally infects human and gorillas and has rarely been observed in other primates (<xref rid="B121" ref-type="bibr">Vandenberghe et&#160;al., 1964</xref>; <xref rid="B27" ref-type="bibr">Duke, 1980</xref>; <xref rid="B5" ref-type="bibr">Abraham et&#160;al., 2002</xref>). Even though some primates were able to be experimentally infected with <italic toggle="yes">O. volvulus</italic> and in which adult filarial worms can develop (<xref rid="B29" ref-type="bibr">Eberhard et&#160;al., 1991</xref>; <xref rid="B30" ref-type="bibr">Eberhard et&#160;al., 1995</xref>), it is not feasible or practical to use non-human primates as an animal model on which to test a vaccine against onchocerciasis at the early stage due to high cost, logistical limitations, and ethical constraints (<xref rid="B5" ref-type="bibr">Abraham et&#160;al., 2002</xref>; <xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>; <xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>). Another limitation for vaccine development against onchocerciasis is the difficulty to obtain the third-stage infective larvae (L3) without definitive animal hosts infected with the parasite to provide the microfilariae needed to infect blackflies. Infected blackflies by feeding on consented infected individuals are the only source of infective L3. The success in the cryopreservation of infective larvae of <italic toggle="yes">O. volvulus</italic> greatly facilitated the ability to conduct challenge studies in the laboratory (<xref rid="B113" ref-type="bibr">Trpis et&#160;al., 1993</xref>) using the following models.</p><sec id="s2_1"><title>Mouse Diffusion Chamber Model With <italic toggle="yes">O. volvulus</italic>
</title><p>Even though human <italic toggle="yes">O. volvulus</italic> cannot establish infection in rodents, a mouse model was successfully established for evaluating the protective immunity to the larvae of <italic toggle="yes">O. volvulus</italic> within diffusion chambers implanted under the skin of mice (<xref rid="B76" ref-type="bibr">Lange et&#160;al., 1993</xref>). The chamber model allows the humoral and cellular immune components to go through the chamber freely for observation of their effects on L3 in the microenvironment. This chamber model has been successfully used to evaluate the protective immunity induced by the immunization of irradiated L3 and other recombinant vaccine candidates (<xref rid="B76" ref-type="bibr">Lange et&#160;al., 1993</xref>; <xref rid="B77" ref-type="bibr">Lange et&#160;al., 1994</xref>). The mouse model with the implanted chamber was selected as a moderate throughput means to screen for the vaccine candidates (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>). However, the limitation of the mouse chamber model is that the challenged <italic toggle="yes">O. volvulus</italic> L3 only live for a short time and do not develop into adult worms or produce microfilaria, and thus it is not suitable for testing therapeutic vaccines (<xref rid="B5" ref-type="bibr">Abraham et&#160;al., 2002</xref>).</p></sec><sec id="s2_2"><title>Cattle Model With <italic toggle="yes">O. ochengi</italic>
</title><p>
<italic toggle="yes">O. ochengi</italic> is a species of <italic toggle="yes">Onchocerca</italic> that naturally infects cattle. It is closely related to human <italic toggle="yes">O. volvulus</italic> and shares extensive molecule similarity and antigen cross-reactivity (<xref rid="B57" ref-type="bibr">Hoch et&#160;al., 1992</xref>). Both species are endemic in the same areas and transmitted by the same black fly vector <italic toggle="yes">Simulium damnosum</italic>. An epidemiological study showed that humans acquired cross-protection against <italic toggle="yes">O. volvulus</italic> infection by exposure to infected larvae of <italic toggle="yes">O. ochengi</italic> in the same endemic region (<xref rid="B124" ref-type="bibr">Wahl et&#160;al., 1994</xref>; <xref rid="B123" ref-type="bibr">Wahl et&#160;al., 1998</xref>). There is evidence for naturally acquired protective immunity against <italic toggle="yes">O. ochengi</italic> infection in cattle, similar to those individuals with putative resistance to <italic toggle="yes">O. volvulus</italic> (<xref rid="B123" ref-type="bibr">Wahl et&#160;al., 1998</xref>). These putatively immune cattle were significantly less susceptible to heavy field challenge than were na&#239;ve control cattle (<xref rid="B110" ref-type="bibr">Tchakoute et&#160;al., 2006</xref>). Experimental infection with <italic toggle="yes">O. ochengi</italic> demonstrated similar kinetics of an immune response as those reported in <italic toggle="yes">O. volvulus</italic> infection (<xref rid="B112" ref-type="bibr">Trees et&#160;al., 2000</xref>). A serological investigation in cattle for recombinant proteins of <italic toggle="yes">O. volvulus</italic> revealed a high degree of immunological cross-reactivity between the antigens of <italic toggle="yes">O. volvulus</italic> and <italic toggle="yes">O. ochengi</italic> (<xref rid="B46" ref-type="bibr">Graham et&#160;al., 1999</xref>). These studies demonstrate the similarity in the biological and immunological properties between <italic toggle="yes">O. ochengi</italic> in cattle and <italic toggle="yes">O. volvulus</italic> in humans. Such findings suggest that the naturally infected cattle/<italic toggle="yes">O. ochengi</italic> model can be used to test prophylactic or therapeutic vaccines and/or drugs under experimental and field conditions (<xref rid="B112" ref-type="bibr">Trees et&#160;al., 2000</xref>; <xref rid="B110" ref-type="bibr">Tchakoute et&#160;al., 2006</xref>; <xref rid="B93" ref-type="bibr">Makepeace and Tanya, 2016</xref>). This bovine model of <italic toggle="yes">O. ochengi</italic> has been successfully used to test therapeutic drugs and protective immunity of onchocerciasis by the WHO Drug Development Research Macrofil program and the Edna McConnell Clark Foundation vaccine development program in experimental infections in Liverpool and field infections in northern Cameroon (<xref rid="B112" ref-type="bibr">Trees et&#160;al., 2000</xref>; <xref rid="B110" ref-type="bibr">Tchakoute et&#160;al., 2006</xref>; <xref rid="B92" ref-type="bibr">Makepeace et&#160;al., 2009</xref>; <xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>; <xref rid="B15" ref-type="bibr">Bah et&#160;al., 2021</xref>).</p></sec><sec id="s2_3"><title>
<italic toggle="yes">Brugia malayi</italic>-Gerbil Model</title><p>Since <italic toggle="yes">B. malayi</italic> and <italic toggle="yes">O. volvulus</italic> are two genetically related filariae that share a similar life cycle and antigenicity, the <italic toggle="yes">B. malayi</italic>-gerbil model can be used to reflect the efficacy of the onchocerciasis vaccine (<xref rid="B98" ref-type="bibr">Morris et&#160;al., 2013</xref>; <xref rid="B10" ref-type="bibr">Arumugam et&#160;al., 2016</xref>). Gerbils are permissive to the infection of human filarial <italic toggle="yes">B. malayi</italic> by subcutaneous or peritoneal injection of L3. The adult worms can be developed in the spermatic cord and lymphatic vessels, and microfilariae appear in blood 79 to 116 days postinfection and last for at least 26 weeks (<xref rid="B13" ref-type="bibr">Ash and Riley, 1970</xref>; <xref rid="B98" ref-type="bibr">Morris et&#160;al., 2013</xref>). Vaccination of gerbils with irradiated <italic toggle="yes">B. malayi</italic> L3 induced a 56%&#8211;91% reduction in recovered worms and a complete protection against microfilaremia (<xref rid="B132" ref-type="bibr">Yates and Higashi, 1985</xref>). This is a potential backup model to test the vaccine efficacy of the homologues of <italic toggle="yes">O. volvulus</italic> vaccine candidates for preventive, therapeutic, or even transmission-blocking vaccines (<xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>).</p></sec></sec><sec id="s3"><title>Acquired Immunity Against <italic toggle="yes">O. volvulus</italic> Infection in Humans</title><p>There is strong epidemiological evidence showing that acquired immunity against <italic toggle="yes">O. volvulus</italic> infection occurs in some people living in endemic areas. The population in hyperendemic regions with age &gt;40 had a trend of decreased skin microfilariae (mf) density (<xref rid="B28" ref-type="bibr">Duke and Moore, 1968</xref>) or reduced number of adult worm-caused skin nodules (<xref rid="B9" ref-type="bibr">Albiez et&#160;al., 1984</xref>), indicating that chronic infections with <italic toggle="yes">O. volvulus</italic> may have developed a means of limiting further infections, although some of the individuals could be less susceptible to worm infection irrelevant to adaptive immunity. About 1%&#8211;5% of the population in hyperendemic areas do not exhibit patent infection or any clinical symptoms after living in endemic areas for extended periods of time and keeping constant exposure to the infection (<xref rid="B40" ref-type="bibr">Gallin et&#160;al., 1988</xref>; <xref rid="B90" ref-type="bibr">MacDonald et&#160;al., 2002</xref>). These individuals are believed to acquire immunity against infection of <italic toggle="yes">O. volvulus</italic> referred to as putatively immune (PI) (<xref rid="B34" ref-type="bibr">Elson et&#160;al., 1994</xref>). Another indication of acquired immunity is concomitant immunity, induced by the current infection to prevent newly infective L3 from developing into adult worms in order to keep a stable adult worm burden (<xref rid="B97" ref-type="bibr">Mitchell, 1990</xref>; <xref rid="B90" ref-type="bibr">MacDonald et&#160;al., 2002</xref>). This immunity is directed not against the concurrently infected adult worms or the microfilaria in infected subjects but against the reinfection with new L3. The acquired immunity was also observed in cattle. The cattle raised in endemic areas without detectable parasites were significantly less susceptible to the challenge with <italic toggle="yes">O. ochengi</italic> than age-matched na&#239;ve cattle (<xref rid="B110" ref-type="bibr">Tchakoute et&#160;al., 2006</xref>).</p><p>Understanding the immunological mechanisms underlying the protective immunity in PI subjects can lead to the identification of antigens involved in the protective immunity as vaccine targets against this infection. Immune sera collected from PI people specifically recognized many antigens in L3, L4, or microfilaria compared to sera from infected people, indicating that PI develop unique antibody responses that may be related to the protective immunity (<xref rid="B62" ref-type="bibr">Irvine et&#160;al., 1997</xref>). Previous studies have shown some associations between immunity and defined antibody and/or cellular responses in exposed individuals. Infection with <italic toggle="yes">O. volvulus</italic> induced strong IgG and subtype IgG responses to a 20-kDa antigen (GP20) in <italic toggle="yes">O. volvulus</italic>, especially with a high level of IgG3 in putatively immune persons, which indicates its importance in acquired immunity to onchocerciasis (<xref rid="B18" ref-type="bibr">Boyer et&#160;al., 1991</xref>; <xref rid="B107" ref-type="bibr">Stewart et&#160;al., 1995</xref>). Cellular response measurement demonstrated that PBMCs collected from PI individuals produced enhanced levels of IL-5 (Th-2), INF-&#611; (Th-1), and a higher level of GM-CSF responses than the infected group against <italic toggle="yes">O. volvulus</italic> larval/adult antigens, indicating that those PI have distinct antigen-specific cytokine responses (<xref rid="B115" ref-type="bibr">Turaga et&#160;al., 2000</xref>). PI individuals showed significantly higher antigen-specific IL-2 (<xref rid="B125" ref-type="bibr">Ward et&#160;al., 1988</xref>) and INF-&#933; (<xref rid="B33" ref-type="bibr">Elson et&#160;al., 1995</xref>), indicating that Th-1 like responses are associated with immunity to onchocerciasis in putatively immune persons; however, other researchers did not find the correlation of cellular response with protective immunity in PBMCs from PI subjects (<xref rid="B40" ref-type="bibr">Gallin et&#160;al., 1988</xref>). All results indicate that putative immunity is associated with mixed Th1/Th2 responses against <italic toggle="yes">O. volvulus</italic> larvae (<xref rid="B47" ref-type="bibr">Greene et&#160;al., 1985</xref>; <xref rid="B115" ref-type="bibr">Turaga et&#160;al., 2000</xref>; <xref rid="B90" ref-type="bibr">MacDonald et&#160;al., 2002</xref>).</p><p>Another study observed that neutrophils or other immune effective cells (e.g., eosinophils) collected from endemic-infected or non-infected individuals (PI) adhered to infective L3 in the presence of specific IgG in their sera; it promoted the killing of L3 or inhibited the molting of L3 to fourth-stage larvae <italic toggle="yes">in vitro</italic> (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>), indicating that this antibody-dependent cell-mediated cytotoxicity (ADCC) against L3 is involved in the immunological defense mechanism (<xref rid="B78" ref-type="bibr">Leke et&#160;al., 1989</xref>; <xref rid="B68" ref-type="bibr">Johnson et&#160;al., 1991</xref>; <xref rid="B67" ref-type="bibr">Johnson et&#160;al., 1994</xref>). These findings further suggest that specific protective immunity may occur in <italic toggle="yes">O. volvulus</italic> natural infection.</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Granulocytes attaching and degranulating on the surface of larval <italic toggle="yes">O. volvulus</italic> recovered from a diffusion chamber, implanted in mouse immunized with irradiated <italic toggle="yes">O. volvulus</italic> third-stage larvae, reprinted from <xref rid="B5" ref-type="bibr">Abraham et&#160;al. (2002)</xref>, with permission.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-12-869039-g001.jpg"/></fig></sec><sec id="s4"><title>Proof of Concept Using Irradiated Larvae</title><p>Infective larval worms that undergo attenuation through radiation, ultraviolet light, or other means have been used experimentally to investigate their vaccine efficacy and commercially to produce veterinary vaccines against canine ancylostomiasis (hookworm infection) (<xref rid="B106" ref-type="bibr">Steves et&#160;al., 1973</xref>) and bovine dictyocaulus lungworm infection (<xref rid="B95" ref-type="bibr">McKeand, 2000</xref>). UV-irradiated <italic toggle="yes">Ascaris suum</italic> eggs containing the infective larvae also induced significant protective immunity against a challenge infection (<xref rid="B120" ref-type="bibr">Urban and Tromba, 1984</xref>). They provide an early indication for the feasibility of larval antigens to induce protective immunity for human helminth infections, and this strategy was adopted as an initial approach for a human hookworm vaccine initiative (<xref rid="B102" ref-type="bibr">Schneider et&#160;al., 2011</xref>).</p><p>This approach was also used to determine if protective immunity can be induced by the irradiated L3 of <italic toggle="yes">O. volvulus</italic> at the early vaccine development stage. Mice immunized with a single dose of irradiated L3 of <italic toggle="yes">O. volvulus</italic> significantly reduced the survival of challenged <italic toggle="yes">O. volvulus</italic> L3 in implanted diffusion chambers; however, killed L3 could not induce the protective immunity indicating that irradiated L3 induces protective immunity that requires L3 to be alive, possibly related to the fact that living L3 can secrete proteins (<xref rid="B76" ref-type="bibr">Lange et&#160;al., 1993</xref>). Immunization induced by irradiated L3 induced high levels of antibody responses, including IgG1, IgG2a/2b, IgA, IgE, and IgM, which recognized <italic toggle="yes">O. volvulus</italic> L3 and adult antigens (<xref rid="B133" ref-type="bibr">Yutanawiboonchai et&#160;al., 1996</xref>). The killing of challenged larvae in immunized mice required direct contact with host immune cells, especially eosinophils. The protective immunity was associated with increased levels of IL-5, IL-4 (<xref rid="B77" ref-type="bibr">Lange et&#160;al., 1994</xref>), and IgE (<xref rid="B4" ref-type="bibr">Abraham et&#160;al., 2004</xref>), but not with INF-&#933; response (<xref rid="B77" ref-type="bibr">Lange et&#160;al., 1994</xref>; <xref rid="B70" ref-type="bibr">Johnson et&#160;al., 1998</xref>), indicating that Th-2 response and eosinophil effector cells are important for the irradiated L3-induced protective immunity against a challenge infection with <italic toggle="yes">O. volvulus</italic>.</p><p>Cattle immunized with irradiated L3 of <italic toggle="yes">O. ochengi</italic> acquired sterile protection against experimental challenge and significant protection against natural infection in the field with a significantly reduced nodule load and microfilaria count as well. These results provide evidence of protective immunity induced by the irradiated L3 and the proof of principle for immunoprophylaxis under experimental challenge or field natural infection (<xref rid="B110" ref-type="bibr">Tchakoute et&#160;al., 2006</xref>). The proof of principle for vaccine efficacy against onchocerciasis in naturally exposed cattle has been also demonstrated against <italic toggle="yes">O. lienalis</italic> in cattle vaccinated with microfilaria extracts (<xref rid="B111" ref-type="bibr">Townson and Bianco, 1982</xref>).</p><p>Although significant or complete protection can be induced by the immunization of irradiated L3 against <italic toggle="yes">O. volvulus</italic> infection, the safety concern for the use of living larvae and the difficulties to obtain large quantity of infective L3 from infected blackflies has limited its application in human vaccine. However, the immune sera from animals immunized with irradiated L3 have been used to identify those L3 antigens potentially involved in the protective immunity and thus promising vaccine candidates. A similar approach was used to identify the first human hookworm vaccine candidate to enter phase 1 clinical trials, an antigen known as Na-ASP-2 (<xref rid="B17" ref-type="bibr">Bethony et&#160;al., 2008</xref>), before revising human hookworm vaccine candidates to focus on adult stage antigens (<xref rid="B7" ref-type="bibr">Adegnika et&#160;al., 2021</xref>).</p></sec><sec id="s5"><title>Roadmap to Identify Vaccine Candidates</title><p>Both prophylactic and therapeutic vaccines have been considered for control of onchocerciasis. An effective prophylactic vaccine should protect vulnerable populations living in endemic areas against <italic toggle="yes">O. volvulus</italic> new infections, especially for children 1&#8211;5 years old before being exposed to the infection. The therapeutic vaccine aims at reducing the adult worm burden and microfilariadermia that cause pathology. Both preventive and therapeutic vaccines could also contribute to lower transmission rates in the endemic region to complement and enhance the MDA with ivermectin endgame or reduce the use of ivermectin, thus potentially reducing the emergence of drug resistance (<xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>).</p><p>A traditional roadmap to develop a vaccine against infectious diseases includes identifying vaccine candidates through immunological approaches to identify antigens recognized by the protective immune sera. Immunoscreening of a stage-specific cDNA library of <italic toggle="yes">O. volvulus</italic> with the sera from individuals who acquired protective immunity against infection after many years of exposure to natural infection in endemic areas or developed concomitant immunity (<xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>) is the major approach to identifying the immunodominant antigens with potential as vaccine candidates. The antigens recognized by these protective sera could be the promising targets of prophylactic and/or therapeutic vaccines against <italic toggle="yes">O. volvulus</italic> infection (<xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>). The construction of cDNA libraries from critical life-cycle stages for the establishment of <italic toggle="yes">O. volvulus</italic> infection including infective L3 and the molting L3 (mL3), or microfilariae (Mf), has provided an important platform to screen for such vaccine targets.</p><p>However, some protective antigens with essential functions to maintain the life cycle of parasites may not be exposed to the host immune system during natural infection, such as digestive proteases that coat on the intestinal tract of the target parasite. These &#8220;hidden antigens&#8221; with essential functions cannot be identified using conventional immunological approaches (<xref rid="B58" ref-type="bibr">Hotez et&#160;al., 2016</xref>). In addition, parasitic helminths secrete a lot of proteins with immunomodulatory functions to reduce host immune response as a survival strategy to evade host immune attack. These immunomodulatory proteins may not induce a strong immune response during natural infection and therefore may not be identified by the immunological approach (<xref rid="B96" ref-type="bibr">McSorley et&#160;al., 2013</xref>). Biochemical or functional analyses of parasite molecules using newly developed proteomics, secretomics, and metabolomics technologies provide new approaches to identify vaccine candidates with functions essential for the survival of parasites. Many functional proteins have been identified in the excretory/secretory products (ESPs) of <italic toggle="yes">O. volvulus</italic> that have potential as vaccine candidates (<xref rid="B122" ref-type="bibr">Vanhamme et&#160;al., 2020</xref>).</p><p>As more genome and transcriptome databases for <italic toggle="yes">Onchocerca</italic> spp. and other related nematodes become available, a faster and novel approach to vaccine discovery from genome analysis known as &#8220;reverse vaccinology&#8221; has been adopted to design vaccines against parasites (<xref rid="B72" ref-type="bibr">Kanampalliwar, 2020</xref>). By using bioinformatics tools, the whole genome sequences of a pathogen or related pathogens can be <italic toggle="yes">in silico</italic> analyzed and screened to identify DNA sequences that encode proteins bearing essential functions and vaccine properties, or immunogenic epitopes for making multi-epitope vaccines. The enormous genome sequencing information and the rise of bioinformatics have triggered a new era of vaccine research and development of the so-called &#8220;third generation&#8221; of vaccinology (<xref rid="B24" ref-type="bibr">de la Fuente and Contreras, 2021</xref>). Transcriptomic analyses of L3, mL3, Mf, and adult filarial stages also accelerate the identification of stage-specific antigens (<xref rid="B16" ref-type="bibr">Bennuru et&#160;al., 2016</xref>) and, accordingly, could identify genes essential for the early establishment of infection in the host, therefore the important targets for prophylactic vaccines of onchocerciasis (<xref rid="B79" ref-type="bibr">Lizotte-Waniewski et&#160;al., 2000</xref>). The overall roadmap to making vaccines against onchocerciasis is summarized in <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>The roadmap to making vaccine against human onchocerciasis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-12-869039-g002.jpg"/></fig></sec><sec id="s6"><title>Lead <italic toggle="yes">O. volvulus</italic> Vaccine Candidates</title><p>Based on the observations highlighted above, two strategies are extensively used to identify antigens from <italic toggle="yes">O. volvulus</italic> with vaccine potential. One is the immunoscreening of stage-specific cDNA libraries including those critical for establishment of <italic toggle="yes">O. volvulus</italic> infection (L3 and mL3) with sera from people living in endemic areas who are putatively immune or from animals immunized with irradiated L3 and acquired protective immunity against challenge infection (<xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>; <xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>). Another is to identify functional proteins that are essential during the infection process or maintenance of the life cycle in the host by analyzing the <italic toggle="yes">O. volvulus</italic> genome or transcriptome (<xref rid="B79" ref-type="bibr">Lizotte-Waniewski et&#160;al., 2000</xref>) or by studying functional homologs that induce protective immunity in other nematode host&#8211;parasite systems (<xref rid="B48" ref-type="bibr">Gregory et&#160;al., 2000</xref>). Some of the functional proteins were found to be present as excretory/secretory products (ESPs) in the nodule fluid or secreted by L3 during infections. Analysis of ESPs in nodule fluid in cows infected with <italic toggle="yes">O. ochengi</italic> identified 85 proteins with drug or vaccine potential (<xref rid="B31" ref-type="bibr">Eberle et&#160;al., 2015</xref>). Vaccination with these crucial molecules may induce immune responses that block or interfere with the establishment of the parasite in the host (<xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>; <xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>). Another 26 protein antigens were identified through immunoscreening of a cDNA library with different protective sera, 12 of which demonstrated partial or significant protection when tested in the <italic toggle="yes">O. volvulus</italic> mouse model (<xref rid="B3" ref-type="bibr">Abraham et&#160;al., 2001</xref>; <xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>; <xref rid="B85" ref-type="bibr">Lustigman et&#160;al., 2003</xref>). Following are the major identified vaccine candidates for onchocerciasis (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>The characteristics of major vaccine candidates for onchocerciasis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Antigen</th><th valign="top" align="center" rowspan="1" colspan="1">Function(s)</th><th valign="top" align="center" rowspan="1" colspan="1">Localization</th><th valign="top" align="center" rowspan="1" colspan="1">Size</th><th valign="top" align="center" rowspan="1" colspan="1">Immune sera used to clone</th><th valign="top" align="center" rowspan="1" colspan="1">Protective evidence</th><th valign="top" align="center" rowspan="1" colspan="1">Expressed host</th><th valign="top" align="center" rowspan="1" colspan="1">Adjuvant</th><th valign="top" align="center" rowspan="1" colspan="1">Worm reduction%</th><th valign="top" align="center" rowspan="1" colspan="1">Immu effector</th><th valign="top" align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" rowspan="2" align="left" colspan="1">Ov-RAL-2</td><td valign="top" rowspan="2" align="left" colspan="1">Novel, nematode-specific SXP/RAL-2 family</td><td valign="top" rowspan="2" align="left" colspan="1">Larval/adult hypodermis; ES</td><td valign="top" rowspan="2" align="center" colspan="1">17 kDa</td><td valign="top" rowspan="2" align="left" colspan="1">Rabbit anti-L3, PI sera</td><td valign="top" rowspan="2" align="left" colspan="1">-Recognized by PI sera<break/>-Ocular pathology<break/>-Protective homologues in Ascaris hookworm, filarial</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">BC/FCA<break/>Alum</td><td valign="top" align="center" rowspan="1" colspan="1">51%&#8211;60%<break/>39% (Hess)</td><td valign="top" rowspan="2" align="left" colspan="1">IgG1, IgG3</td><td valign="top" rowspan="2" align="left" colspan="1"> (<xref rid="B41" ref-type="bibr">Gallin et&#160;al., 1989</xref>; <xref rid="B19" ref-type="bibr">Bradley et&#160;al., 1993</xref>; <xref rid="B20" ref-type="bibr">Chakravarti et&#160;al., 1996</xref>; <xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yeast</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="center" rowspan="1" colspan="1">24% (Hess)</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Ov-103</td><td valign="top" rowspan="2" align="left" colspan="1">Novel, surface-associate antigen</td><td valign="top" rowspan="2" align="left" colspan="1">Cuticle and hypodermis of L3, Mf</td><td valign="top" rowspan="2" align="center" colspan="1">15 kDa</td><td valign="top" rowspan="2" align="left" colspan="1">Chimpanzee infected sera</td><td valign="top" rowspan="2" align="left" colspan="1">-Recognized by PI sera<break/>-Antibody-mediated ADCC</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="center" rowspan="1" colspan="1">8%</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" rowspan="2" align="left" colspan="1">(<xref rid="B83" ref-type="bibr">Lustigman et&#160;al., 1992b</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yeast</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="center" rowspan="1" colspan="1">30%</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1, IgG3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ov-ALT-1</td><td valign="top" align="left" rowspan="1" colspan="1">Abundant larval transcript, secreted larval acidic protein</td><td valign="top" align="left" rowspan="1" colspan="1">L3 granules esophagus</td><td valign="top" align="center" rowspan="1" colspan="1">22 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">PI sera</td><td valign="top" align="left" rowspan="1" colspan="1">-Recognized by PI<break/>-Secreted<break/>-L3-specific<break/>-Protective homologue in <italic toggle="yes">B. malayi</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Freund&#8217;s<break/>Alum</td><td valign="top" align="center" rowspan="1" colspan="1">36%<break/>42% combined with other 7 antigens<break/>0%</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1, IgG3</td><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B71" ref-type="bibr">Joseph et&#160;al., 1998</xref>), (<xref rid="B131" ref-type="bibr">Wu et&#160;al., 2004</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OvB8</td><td valign="top" align="left" rowspan="1" colspan="1">Novel, secreted</td><td valign="top" align="left" rowspan="1" colspan="1">All stages, esophagus body cavity in molting L3</td><td valign="top" align="center" rowspan="1" colspan="1">66 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">PI sera</td><td valign="top" align="left" rowspan="1" colspan="1">-Recognized by PI<break/>-Involved in molting</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="center" rowspan="1" colspan="1">46%<break/>decrease L3 to L4 molting</td><td valign="top" align="left" rowspan="1" colspan="1">Th2, IgG1</td><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B3" ref-type="bibr">Abraham et&#160;al., 2001</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ov-TMY-1</td><td valign="top" align="left" rowspan="1" colspan="1">Tropomyosin</td><td valign="top" align="left" rowspan="1" colspan="1">Cuticle and muscle of microfilariae and L3 secreted</td><td valign="top" align="center" rowspan="1" colspan="1">33 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">Recognized by protective immune sera</td><td valign="top" align="left" rowspan="1" colspan="1">-Antibody inversely correlated with the densities of Mf<break/>-Protective homologue in <italic toggle="yes">O. lienalis</italic> and <italic toggle="yes">A. viteae</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic> fused with MBP</td><td valign="top" align="left" rowspan="1" colspan="1">Freund&#8217;s</td><td valign="top" align="center" rowspan="1" colspan="1">48%&#8211;62%</td><td valign="top" align="left" rowspan="1" colspan="1">IgG</td><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B65" ref-type="bibr">Jenkins et&#160;al., 1998</xref>)</td></tr><tr><td valign="top" rowspan="2" align="left" colspan="1">Ov-CPI-2</td><td valign="top" rowspan="2" align="left" colspan="1">Cysteine protease inhibitor, secreted</td><td valign="top" rowspan="2" align="left" colspan="1">Hypodermis and the basal layer of the cuticle of L3 and female adult worm</td><td valign="top" rowspan="2" align="center" colspan="1">17 kDa</td><td valign="top" rowspan="2" align="left" colspan="1">IrL3 immune sera</td><td valign="top" rowspan="2" align="left" colspan="1">-Recognized by irL3 sera and human PI<break/>-Cysteine protease inhibitor<break/>-Secreted<break/>-immunomodulatory<break/>-96%&#8211;100% inhibition of L3 to L4 molting<break/>-Protective homologues in <italic toggle="yes">B. malayi</italic> and <italic toggle="yes">A. viteae</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic> and yeast)</td><td valign="top" align="left" rowspan="1" colspan="1">Alum<break/>Freund&#8217;s</td><td valign="top" align="center" rowspan="1" colspan="1">30%<break/>42% combined with other 7 antigens</td><td valign="top" rowspan="2" align="left" colspan="1">Th2/1<break/>IgG-mediated ADCC</td><td valign="top" rowspan="2" align="left" colspan="1">(<xref rid="B82" ref-type="bibr">Lustigman et&#160;al., 1992a</xref>; <xref rid="B21" ref-type="bibr">Cho-Ngwa et&#160;al., 2010</xref>; <xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ov-B20</td><td valign="top" align="left" rowspan="1" colspan="1">Novel, nematode specific</td><td valign="top" align="left" rowspan="1" colspan="1">Larval hypodermic and cuticle</td><td valign="top" align="center" rowspan="1" colspan="1">50 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">Recognized by irL3 sera</td><td valign="top" align="left" rowspan="1" colspan="1">-Larval antigen<break/>-Recognized by irL3 sera<break/>-Protective homologue in <italic toggle="yes">A. viteae</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Freund&#8217;s</td><td valign="top" align="center" rowspan="1" colspan="1">42% combined with other 7 antigens</td><td valign="top" align="left" rowspan="1" colspan="1">Antibody</td><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B64" ref-type="bibr">Jenkins et&#160;al., 1996</xref>).</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ov-FAR-1</td><td valign="top" align="left" rowspan="1" colspan="1">fatty acid and retinol binding protein secreted</td><td valign="top" align="left" rowspan="1" colspan="1">Major secreted protein, located in L3 cuticle</td><td valign="top" align="center" rowspan="1" colspan="1">20 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">Recognized by irL3 sera</td><td valign="top" align="left" rowspan="1" colspan="1">-Recognized by anti-L3 and human PI<break/>-Major secreted<break/>-Retinol-binding<break/>-Homologue in <italic toggle="yes">A. viteae</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Freund&#8217;s</td><td valign="top" align="center" rowspan="1" colspan="1">36%&#8211;55% worm reduction in jirds/A. viteae</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B64" ref-type="bibr">Jenkins et&#160;al., 1996</xref>; <xref rid="B74" ref-type="bibr">Kennedy et&#160;al., 1997</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ov-CHI-1</td><td valign="top" align="left" rowspan="1" colspan="1">Chitiase</td><td valign="top" align="left" rowspan="1" colspan="1">L3</td><td valign="top" align="center" rowspan="1" colspan="1">54 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">Genome</td><td valign="top" align="left" rowspan="1" colspan="1">-Functional (chitinase)<break/>-Protective homologues in B. malayi, <italic toggle="yes">W. bancrofti</italic>, <italic toggle="yes">A. viteae</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">DNA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">53%</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1</td><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B52" ref-type="bibr">Harrison et&#160;al., 1999</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ov-ASP-1</td><td valign="top" align="left" rowspan="1" colspan="1">Nematode activated secret protein</td><td valign="top" align="left" rowspan="1" colspan="1">Secreted, larval abundant, esophagus glandular</td><td valign="top" align="center" rowspan="1" colspan="1">15 kDa</td><td valign="top" align="left" rowspan="1" colspan="1">PI sera, mice anti-Ov-L3</td><td valign="top" align="left" rowspan="1" colspan="1">-Secreted<break/>-Recognized by PI<break/>-Immunogenic</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">E. coli</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">Freund&#8217;s<break/>Alum</td><td valign="top" align="center" rowspan="1" colspan="1">42%<break/>44%</td><td valign="top" align="left" rowspan="1" colspan="1">IgG1, IgG2a</td><td valign="top" align="left" rowspan="1" colspan="1"> (<xref rid="B89" ref-type="bibr">MacDonald et&#160;al., 2004</xref>)</td></tr></tbody></table></table-wrap><sec id="s6_1"><title>Ov-CPI-2 (Ov7)</title><p>OV7 was identified by immunoscreening an adult <italic toggle="yes">O. volvulus</italic> cDNA library with chimpanzee antiserum generated against irradiated infective larvae. Western blot with antibody revealed that the native antigen of OV7 was 17 kDa located in L3, L4, and adult worms. Immunoelectron microscopy showed that OV7 was located in the hypodermis and the basal layer of the cuticle of L3 and female adult worm, and in the eggshell around developing microfilariae (<xref rid="B81" ref-type="bibr">Lustigman et&#160;al., 1991</xref>). Sequence alignment reveals that OV7 belongs to the cystatin superfamily of cysteine proteinase inhibitors and the recombinant OV7 protein demonstrated its activity to inhibit cysteine proteinases at physiological conditions, therefore renamed as Ov-CPI-2 (<xref rid="B82" ref-type="bibr">Lustigman et&#160;al., 1992a</xref>). Ov-CPI-2 is also the most abundant protein in L3 and molting L3 recognized by the sera from chronically infected human with putative immunity (<xref rid="B21" ref-type="bibr">Cho-Ngwa et&#160;al., 2010</xref>). Ov-CPI-2 contains a hydrophobic leader sequence, indicating its secreted extracellular function involved in the survival of the parasite in the host. The cystatin functional activity and its location suggest the role of OV7 in the regulation of parasite cysteine proteases during molting or hatching of the worms or in regulating host immune responses (<xref rid="B82" ref-type="bibr">Lustigman et&#160;al., 1992a</xref>). The <italic toggle="yes">E. coli</italic> expressed soluble Ov-CPI-2 protein demonstrated strong inhibitory activity on human cysteine protease cathepsins L and S (<xref rid="B103" ref-type="bibr">Schonemeyer et&#160;al., 2001</xref>). Further studies found that Ov-CPI-2 suppressed the antigen-driven proliferation of human PBMC, especially monocytes, through stimulating IL-10, indicating that Ov-CPI-2 is a strong immunomodulatory protein causing host cellular hyporesponsiveness, and therefore an essential factor for immune evasion and support for the survival of <italic toggle="yes">O. volvulus</italic> within its human host (<xref rid="B103" ref-type="bibr">Schonemeyer et&#160;al., 2001</xref>). It was further found that the molting of L3 to L4 was reduced up to 96%&#8211;100% when L3 were <italic toggle="yes">in vitro</italic> incubated with purified human anti-Ov-CPI-2 IgG in the presence of human neutrophils, indicating that Ov-CPI-2 is necessary for the molting of L3 to L4, the critical step to establishing parasitism in the terminal host. The immune response to Ov-CPI-2 may be involved in the ADCC-related mechanism in the inhibition of L3 molting (<xref rid="B85" ref-type="bibr">Lustigman et&#160;al., 2003</xref>; <xref rid="B21" ref-type="bibr">Cho-Ngwa et&#160;al., 2010</xref>). The homologues of Ov-CPI-2 were also identified in <italic toggle="yes">B. malayi</italic> (<xref rid="B49" ref-type="bibr">Gregory et&#160;al., 1997</xref>) and <italic toggle="yes">Acanthocheilonema viteae</italic> (<xref rid="B53" ref-type="bibr">Hartmann et&#160;al., 1997</xref>). However, vaccination with Bm-CPI-2 in its original form did not confer protection against <italic toggle="yes">B. malayi</italic> L3 challenge infection in gerbils but altered the location of adult worms from the lymphatic vessels to the heart and lungs (<xref rid="B12" ref-type="bibr">Arumugam et&#160;al., 2014b</xref>). However, vaccination with a genetically modified Bm-CPI-2 reduced adult parasite numbers and affected the fertility of female worms following a subcutaneous challenge of gerbils with <italic toggle="yes">B. malayi</italic> infective larvae (<xref rid="B12" ref-type="bibr">Arumugam et&#160;al., 2014b</xref>)</p></sec><sec id="s6_2"><title>Ov-RAL-2</title><p>A cDNA encoding a 17-kDa protein called Ov-RAL-2 (&#955;RAL-2, or Ov17) was isolated from an <italic toggle="yes">O. volvulus</italic> adult cDNA expression library recognized by rabbit anti-living L3 sera. Most individuals living in the endemic areas produced antibody anti-Ov-RAL-2, indicating its strong antigenicity during natural infection (<xref rid="B119" ref-type="bibr">Unnasch et&#160;al., 1988</xref>; <xref rid="B41" ref-type="bibr">Gallin et&#160;al., 1989</xref>). Individuals with the anti-Ov-RAL-2 antibody displayed significantly less chance of developing ocular pathology associated with <italic toggle="yes">O. volvulus</italic> infection, indicating that Ov-RAL-2 may be involved with a mechanism of ocular pathology (<xref rid="B41" ref-type="bibr">Gallin et&#160;al., 1989</xref>). Recombinant Ov-RAL-2 expressed in <italic toggle="yes">E. coli</italic> elicited significant and sustained proliferation of lymphocytes from chimpanzees immunized with live or irradiated <italic toggle="yes">O. volvulus</italic> L3, indicating that Ov-RAL-2 is involved in the L3-induced protective immune responses (<xref rid="B20" ref-type="bibr">Chakravarti et&#160;al., 1996</xref>). The native Ov-RAL-2 was localized in the hypodermis of adult and larval stages of the parasite. Full-length cDNA clones encoding Ov-RAL-2 contain a polyglutamine tract immediately after a putative leader sequence. The poly-Q tract at the N-terminus is not related to the antibody response during natural infection (<xref rid="B19" ref-type="bibr">Bradley et&#160;al., 1993</xref>).</p><p>Ov-RAL-2 is a member of the SXP/RAL-2 protein family that exists in various nematode species containing two conserved motifs: SXP1 and SXP2. These SXP/RAL-2 family proteins include the As16 protein (<xref rid="B126" ref-type="bibr">Wei et&#160;al., 2017</xref>) and Asc l 5 (<xref rid="B8" ref-type="bibr">Ahumada et&#160;al., 2020</xref>) from <italic toggle="yes">Ascaris suum</italic>, WB14 and SXP from <italic toggle="yes">Wuchereria bancrofti</italic> (<xref rid="B99" ref-type="bibr">Pandiaraja et&#160;al., 2010</xref>), and allergen Ani s 5 antigen from <italic toggle="yes">Anisakis simplex</italic> (<xref rid="B42" ref-type="bibr">Garcia-Mayoral et&#160;al., 2014</xref>). The function of this family proteins is not clear; however, the alpha helical structures from Ani s 5 and from recombinant Ov-RAL-2 expressed in <italic toggle="yes">E. coli</italic> and yeast (unpublished) indicate their cation-binding activity involved in the interaction with host immune molecules (<xref rid="B42" ref-type="bibr">Garcia-Mayoral et&#160;al., 2014</xref>). The homologues of Ov-RAL-2 in <italic toggle="yes">A. suum</italic> As14 (<xref rid="B114" ref-type="bibr">Tsuji et&#160;al., 2001</xref>), As16 (<xref rid="B126" ref-type="bibr">Wei et&#160;al., 2017</xref>), and <italic toggle="yes">Ancylostoma caninum</italic> Ac16 (<xref rid="B39" ref-type="bibr">Fujiwara et&#160;al., 2007</xref>) displayed protective immunity when immunized as recombinant proteins against the challenge of the infective larvae. Bm-RAL-2, the Ov-RAL-2 homologue in <italic toggle="yes">B. malayi</italic> sharing 62% sequence identity, contains a DUF148 domain with unknown function by searching the Pfam database (<xref rid="B10" ref-type="bibr">Arumugam et&#160;al., 2016</xref>). Gerbils immunized with recombinant Bm-RAL-2 induced significant worm reduction against <italic toggle="yes">B. malayi</italic> L3 challenge (<xref rid="B10" ref-type="bibr">Arumugam et&#160;al., 2016</xref>).</p></sec><sec id="s6_3"><title>Ov-103</title><p>Ov-103 is a 15-kDa surface-associated antigen of <italic toggle="yes">O. volvulus</italic> identified and isolated from an adult cDNA library with serum from chimpanzee infected with <italic toggle="yes">O. volvulus</italic>. It is present in the basal layer of the cuticle and the hypodermis of microfilariae and adult female worms (Lustigman et&#160;al., 1992). It was also identified to be expressed by <italic toggle="yes">O. volvulus</italic> L3s (<xref rid="B79" ref-type="bibr">Lizotte-Waniewski et&#160;al., 2000</xref>). Ov-103 is an immunodominant antigen recognized by <italic toggle="yes">O. volvulus</italic>-infected human sera, especially more significantly by sera from individuals that have low levels of patent infection. In the experimental infection with <italic toggle="yes">O. volvulus</italic> infective L3, the anti-Ov-103 antibody appeared earlier in chimpanzees with low-level or non-patent infections than those with patent infection. More importantly, the anti-Ov-103 antibody could mediate the killing of nodular microfilariae in the presence of normal human granulocytes <italic toggle="yes">in vitro</italic> (<xref rid="B69" ref-type="bibr">Johnson et&#160;al., 1995</xref>) as well as inhibiting molting of L3 in the presence of neutrophils and monocytes (Lustigman et&#160;al., 1992, <xref rid="B45" ref-type="bibr">George et&#160;al., 2019</xref>). Mice immunized with recombinant Ov-103 formulated with alum induced significant protection against <italic toggle="yes">O. volvulus</italic> L3 challenge in a chamber model (<xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>; <xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>).</p></sec><sec id="s6_4"><title>OV9M</title><p>OV9M was identified and cloned by immunoscreening the <italic toggle="yes">O. volvulus</italic> adult cDNA library using pooled rabbit antisera against L3 and L4 larvae of the parasite. It is a 45-kDa immunodominant calponin-like protein located in the muscle of the different larval stages and adult worms. The antibodies to the OV9M protein are present in endemic residents with both patent and non-patent infection (<xref rid="B61" ref-type="bibr">Irvine et&#160;al., 1994</xref>).</p></sec><sec id="s6_5"><title>Ov-ALT-1</title><p>Immunoscreening of the <italic toggle="yes">O. volvulus</italic> L3 cDNA expression library with a pool of sera from PI individuals living in the endemic regions identified 58 cDNA clones, 6 of which encode a 20-kDa abundant larval transcript protein named Ov-ALT-1. Ov-ALT-1 is a larval stage-specific antigen belonging to a family of secreted larval acidic proteins (SLAPs), being expressed exclusively in late L2 and L3 during growth in the vector. The native Ov-ALT-1 is present in the granules of the glandular esophagus of L3 during growth in the blackfly vector (<xref rid="B71" ref-type="bibr">Joseph et&#160;al., 1998</xref>). It is secreted upon the resumption of development in the definitive host, therefore related to the establishment of infection in human (<xref rid="B131" ref-type="bibr">Wu et&#160;al., 2004</xref>). Individuals in a region of hyperendemicity in Cameroon showed age-associated IgG1 and IgG3 responses to Ov-ALT-1, indicating that immune responses to Ov-ALT-1 are associated with concomitant immunity (<xref rid="B90" ref-type="bibr">MacDonald et&#160;al., 2002</xref>). Mice immunized with recombinant Ov-ALT-1 produced a modest level of protection against challenge with <italic toggle="yes">O. volvulus</italic> L3 larvae (36% reduction of L4 survival rate) (<xref rid="B131" ref-type="bibr">Wu et&#160;al., 2004</xref>). The protective immunity induced by Ov-ALT-1 is consistent with reports of the induction of protective immunity in jirds induced by vaccination with its homologue Bm-ALT-1 in <italic toggle="yes">B. malayi</italic> (<xref rid="B48" ref-type="bibr">Gregory et&#160;al., 2000</xref>). The homologue of Ov-ALT-1 was also identified in the ES products of dog filarial <italic toggle="yes">Dirofilaria immitis</italic> larvae (<xref rid="B35" ref-type="bibr">Frank and Grieve, 1996</xref>; <xref rid="B36" ref-type="bibr">Frank et&#160;al., 1996</xref>).</p></sec><sec id="s6_6"><title>Ov-B20</title><p>Ov-B20 is a larval antigen of <italic toggle="yes">O. volvulus</italic> recognized by sera from cattle vaccinated with irradiated L3 of <italic toggle="yes">O. lienalis</italic>. It contains 460 amino acid residues expressed in developing stages from embryo to L4 larva, but not in the adult (<xref rid="B1" ref-type="bibr">Abdel-Wahab et&#160;al., 1996</xref>). The native Ov-B20 is located in the hypodermis and cuticle of infective larvae. Although vaccination of mice with B20-MBP fusion protein did not induce a reduction of microfilariae of <italic toggle="yes">O. lienalis</italic> in the ears, jirds vaccinated with B20-MBP fusion induced a 49%&#8211;60% adult worm reduction and a 97% reduction in microfilaremia against <italic toggle="yes">A. viteae</italic> infection (<xref rid="B108" ref-type="bibr">Taylor et&#160;al., 1995</xref>). Another <italic toggle="yes">A. viteae</italic>/Mongolian jird model trial with recombinant Ov-B20 induced a host-protective response with 36%&#8211;55% worm reduction following a challenge infection (<xref rid="B64" ref-type="bibr">Jenkins et&#160;al., 1996</xref>).</p></sec><sec id="s6_7"><title>Ov-TMY-1</title><p>Ov-TMY-1 is a 33-kDa tropomyosin located within muscle blocks and the cuticle of microfilariae and infective larvae. It shares 91% identity with its homologues from other nematodes. Anti-Ov-TMY-1 antibodies were abundant in protective sera of mice immunized with <italic toggle="yes">O. volvulus</italic> worm extracts, and the level of anti-Ov-TMY-1 antibodies was inversely correlated with the densities of microfilariae in the skin, indicating that Ov-TMY-1-induced antibody responses may be important in reducing worm burden (<xref rid="B65" ref-type="bibr">Jenkins et&#160;al., 1998</xref>). Recombinant protein containing 136 amino-acid residues from the C-terminus of Ov-TMP-1 induced significant reductions of <italic toggle="yes">O. lienalis</italic> microfilariae (48%&#8211;62%) in a mouse infection model associated with an elevated level of IgG1. Another trial with the same recombinant protein in a jirds/<italic toggle="yes">A. viteae</italic> model revealed 46% adult worm reduction compared to control groups. The anti-Ov-TMY-1 antibodies recognized the native tropomyosin in ES products released by the parasite (<xref rid="B109" ref-type="bibr">Taylor et&#160;al., 1996</xref>). An immunodominant B-cell epitope was mapped to the N terminus of the Ov-TMY-1 protein (AQLLAEEADRKYD) by using sera from mice with protective immunity (<xref rid="B65" ref-type="bibr">Jenkins et&#160;al., 1998</xref>).</p></sec><sec id="s6_8"><title>Ov-CHI-1</title><p>The cDNA coding for <italic toggle="yes">O. volvulus</italic> chitinase was cloned from <italic toggle="yes">O. volvulus</italic> (<italic toggle="yes">Ov-chi-1</italic>) with 54 kDa in size. It is expressed specifically in L3 of <italic toggle="yes">O. volvulus</italic> (<xref rid="B130" ref-type="bibr">Wu et&#160;al., 1996</xref>). Mice immunized with the <italic toggle="yes">Ov-chi-1</italic> DNA vaccine induced significant IgG1 production and partial protection against challenge infection with L3 larvae (53% reduction in L3 survival) in a mouse/chamber model (<xref rid="B52" ref-type="bibr">Harrison et&#160;al., 1999</xref>). The homologues of Ov-CHI-1 in <italic toggle="yes">B. malayi</italic> were recognized by a transmission-blocking monoclonal antibody MF1 (<xref rid="B38" ref-type="bibr">Fuhrman et&#160;al., 1992</xref>). A 43-kDa larval-stage chitinase of <italic toggle="yes">W. bancrofti</italic> was recognized by the sera from infection-free individuals living in an endemic area, indicating its potential protective immunity in bancroftian filariasis (<xref rid="B37" ref-type="bibr">Freedman et&#160;al., 1989</xref>). The homologue in <italic toggle="yes">A. viteae</italic> is believed to be involved in the degradation of the filarial cuticle during molting and thus represents a target of protective immune responses in a phase where the parasite is highly vulnerable (<xref rid="B6" ref-type="bibr">Adam et&#160;al., 1996</xref>). A recent study revealed that chitinase secreted by the helminth <italic toggle="yes">Trichuris suis</italic> L1 larvae mimics host chitinase and displays immunomodulatory properties in Inflammatory lung disease (<xref rid="B32" ref-type="bibr">Ebner et&#160;al., 2021</xref>).</p></sec><sec id="s6_9"><title>OvB8</title><p>OvB8 is a 66-kDa protein recognized by sera from PI individuals living in endemic areas in Liberia and Ecuador. It is present in all stages of the <italic toggle="yes">O. volvulus</italic> parasite, especially located in the basal lamina surrounding the esophagus and the body cavity in molting L3 (<xref rid="B3" ref-type="bibr">Abraham et&#160;al., 2001</xref>). There is no sequence homology to any existing nematode genes except for a homologue in the <italic toggle="yes">B. malayi</italic> EST database (<xref rid="B3" ref-type="bibr">Abraham et&#160;al., 2001</xref>; <xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>). Immunization with recombinant OvB8 protein formulated with alum induced an up to 46% reduction in L3 survival rate and a significant decrease of molting of challenged L3 to L4 in a chamber mouse model (<xref rid="B3" ref-type="bibr">Abraham et&#160;al., 2001</xref>).</p></sec><sec id="s6_10"><title>Ov-FAR-1</title><p>Ov20 is an immunodominant protein recognized by antiserum raised against the infective L3 or human onchocerciasis infection sera. It is a major protein secreted by <italic toggle="yes">O. volvulus</italic> in the nodule with a molecular weight of 20 kDa. The native Ov20 was located in the L3 cuticle and uterine wall of the adult female (<xref rid="B64" ref-type="bibr">Jenkins et&#160;al., 1996</xref>). <italic toggle="yes">E. coli</italic> expressing recombinant Ov20 had strong binding ability to retinol and fatty acids, therefore renamed as fatty acid and retinol-binding protein of <italic toggle="yes">O. volvulus</italic> (Ov-FAR-1). The secondary structure of Ov-FAR-1 contains an alpha-helix in a coiled-coil motif determined by circular dichroism. The retinol-binding activity and the secretion property of Ov-FAR-1 indicate its potential contribution to the eye pathology associated with onchocerciasis, therefore presenting a potential target for drug or vaccine development (<xref rid="B74" ref-type="bibr">Kennedy et&#160;al., 1997</xref>). Indeed, a vaccine trial performed in an <italic toggle="yes">A. viteae</italic>/Mongolian jird model of filariasis displayed a 36%&#8211;55% worm reduction in jirds immunized with recombinant Ov-FAR-1 and followed with a challenge infection (<xref rid="B64" ref-type="bibr">Jenkins et&#160;al., 1996</xref>). In a <italic toggle="yes">B</italic>. <italic toggle="yes">malayi</italic> infection model in gerbils, immunization with r<italic toggle="yes">Bm-</italic>FAR-1 and its homolog r<italic toggle="yes">Bm</italic>-FAR-2 formulated Montanide-720 or alum elicited high titers of antigen-specific IgG, but only gerbils immunized with r<italic toggle="yes">Bm</italic>-FAR-1 formulated with Montanide-720 produced a statistically significant reduction in adult worms (68%) following challenge with <italic toggle="yes">B</italic>. <italic toggle="yes">malayi</italic> infective larvae (<xref rid="B134" ref-type="bibr">Zhan et&#160;al., 2018</xref>).</p></sec><sec id="s6_11"><title>Ov-FBA</title><p>A cDNA encoding the glycolytic enzyme fructose 1,6 bisphosphate aldolase of <italic toggle="yes">O. volvulus</italic> (Ov-FBA-1) was cloned by immunoscreening the <italic toggle="yes">O. volvulus</italic> cDNA library with PI sera. The native Ov-FBA is abundantly expressed in metabolically active tissues, including body wall, muscle, the reproductive tract of adult female worms, cuticle separates during molting, and the channels connecting the esophagus to the cuticle. Strong humoral and cellular immune responses to Ov-FBA-1 were observed in both PI and infected subjects. Despite the absence of immune response in parasite-exposed human populations to this antigen, the recombinant Ov-FBA-1 induced significant protective efficacy in a mouse chamber model with reduction in survival of larvae by 50% (<xref rid="B94" ref-type="bibr">McCarthy et&#160;al., 2002</xref>). This observation gives support for further study of this enzyme as a vaccine candidate in larger animal models.</p></sec><sec id="s6_12"><title>Ov-ASP-1</title><p>Ov-ASP-1 is an activation-associated secreted protein (ASP) belonging to a family of cysteine-rich secretory protein/antigen 5/pathogenesis related-1 proteins (CAP). It is abundantly expressed in L3 of <italic toggle="yes">O. volvulus</italic> with structural similarities to a component of vespid venom. Recombinant Ov-ASP-1 protein induced an angiogenic response after injection (<xref rid="B26" ref-type="bibr">Ding et&#160;al., 2018</xref>) into corneas of naive mice, suggesting its potential function involved in the eye pathology caused by the onchocerciasis (<xref rid="B79" ref-type="bibr">Lizotte-Waniewski et&#160;al., 2000</xref>). <italic toggle="yes">O. volvulus</italic>-infected (INF) and putatively immune (PI) individuals contain high titers of anti-Ov-ASP-1 IgG. Mice immunized with recombinant Ov-ASP-1 formulated with Freund&#8217;s or alum adjuvant produced partial but significant protection against challenge with L3 associated with high titers of Th1-related IgG2a with Freund&#8217;s adjuvant or Th2-skewed IgG1 response with alum (<xref rid="B89" ref-type="bibr">MacDonald et&#160;al., 2004</xref>). The protective immunity was also observed in its homologue of human hookworm <italic toggle="yes">Necator americanus</italic> (<italic toggle="yes">Na</italic>-ASP-2) (<xref rid="B17" ref-type="bibr">Bethony et&#160;al., 2008</xref>). Ov-ASP-1 is very immunogenic; immunization of recombinant Ov-ASP-1 without adjuvant induced high titers of both IgG1 and IgG2a in mice. Further studies revealed that Ov-ASP-1 owns strong immunostimulatory protein and exerts its adjuvanticity when combined with various vaccine antigens or commercial vaccines (<xref rid="B88" ref-type="bibr">MacDonald et&#160;al., 2005</xref>; <xref rid="B56" ref-type="bibr">He et&#160;al., 2009</xref>; <xref rid="B66" ref-type="bibr">Jiang et&#160;al., 2016</xref>; <xref rid="B63" ref-type="bibr">Jain et&#160;al., 2018</xref>).</p></sec><sec id="s6_13"><title>Multi-Epitope Vaccine</title><p>A filarial-conserved multi-epitope subunit vaccine based on 8 identified vaccine candidates was previously assessed in preclinical studies (Ov-103, Ov-RAL-2, Ov-ASP-1, Ov-ALT-1, and Ov-ALT-2, Ov-B20, Ov-RBP-1 and Ov-CHI-1) (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>; <xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>). This multi-epitope construct designated as Ov-DKR-2 contains B- and T-cell epitopes of these 8 immunogenic vaccine antigens. A preliminary immunological test with this multi-epitope vaccine candidate revealed its strong reaction to antibodies in sera from putatively immune or infected individuals living in <italic toggle="yes">O. volvulus</italic>-endemic areas as well as from loiasis individuals, but not with the normal control sera from European individuals. These results support its further evaluation as a vaccine candidate for onchocerciasis (<xref rid="B105" ref-type="bibr">Shey et&#160;al., 2021</xref>). Immuno-informatics tools and high-density peptide array were used to screen the immunodominant epitopes from the same 8 promising vaccine candidates as mentioned above using sera from onchocerciasis patients and healthy controls. The immunodominant linear epitopes were found in these proteins that were specifically recognized by onchocerciasis patient sera. This peptide-based ELISA was developed to evaluate their potential for diagnosing <italic toggle="yes">Onchocerca</italic> infection (with a sensitivity of 75.0% and a specificity of 98.5%) especially the poly-glutamine stretch of Ov-RAL-2, which could be used as a serodiagnostic marker for <italic toggle="yes">O. volvulus</italic> infection. These immunodominant epitope peptides also have potential to be developed as vaccine against onchocerciasis (<xref rid="B75" ref-type="bibr">Lagatie et&#160;al., 2018</xref>).</p></sec></sec><sec id="s7"><title>Down-Selection of Recombinant Protein Vaccines</title><p>To down-select the antigen(s) with the most promising vaccine efficacy as vaccine candidate(s), the following criteria were used to create a priority ranking: (i) with known or essential function required in the infection and survival in the host; (ii) L3 or L4 abundant antigens responsible for the initiation of infection in host; (iii) localized on the surface area immunologically accessible to the immune responses; (iv) recognized by the antibodies from humans with putatively protective immunity (PI) or cattle, chimpanzees, and mice immunized with irradiated larvae; (v) protection identified in a mouse chamber model or the killing (or L3 molting inhibition) of larvae by the antibody in the presence of neutrophil or monocytes <italic toggle="yes">in vitro</italic>; and (vi) presence of the protective homologues in other filarial or nematodes (<xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>; <xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>).</p><p>Based on the selected criteria, 8 of the 12 potential vaccine candidates described above that induced worm reduction between 39% and 69% (<xref rid="B3" ref-type="bibr">Abraham et&#160;al., 2001</xref>; <xref rid="B84" ref-type="bibr">Lustigman et&#160;al., 2002</xref>; <xref rid="B85" ref-type="bibr">Lustigman et&#160;al., 2003</xref>; <xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>) were selected for further evaluation in the mouse chamber model in parallel under the same conditions. These 8 antigens are Ov-CPI-2, Ov-ASP-1, Ov-RAL-2, Ov-ALT-1, Ov-103, Ov-B20, Ov-FBP-1, and Ov-CHI (<xref rid="B86" ref-type="bibr">Lustigman et&#160;al., 2017</xref>). To avoid the potential side effect of the functional cysteine protease inhibitor of Ov-CPI-2 (<xref rid="B50" ref-type="bibr">Gregory and Maizels, 2008</xref>) and to increase its immunogenicity in immunized hosts (<xref rid="B14" ref-type="bibr">Babayan et&#160;al., 2012</xref>), the Asn66 responsible for the asparaginyl endopeptidase inhibitory activity was mutated to Lys66 (<xref rid="B14" ref-type="bibr">Babayan et&#160;al., 2012</xref>) and thus created a mutated form of the inhibitor, Ov-CPI-1M. Seven of the eight down-selected antigens were expressed as soluble recombinant proteins in yeast <italic toggle="yes">Pichia pastoris</italic> and <italic toggle="yes">E. coli</italic> systems at Texas Children&#8217;s Hospital Center for Vaccine Development under strict conditions of quality control. Mice were immunized subcutaneously with each of the purified recombinant proteins formulated with Rehydragel&#8482; LV (alum) for three times before being challenged with L3 in the embedded diffusion chamber. Out of seven vaccine candidates tested, Ov-103, Ov-RAL-2, and Ov-CPI-2M induced protective immunity against <italic toggle="yes">O. volvulus</italic> L3 and the protection was reproducible in separate trials (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>). Mice immunized with recombinant Ov-103 expressed in yeast induced a significant 30% reduction in L3 survival and a 63% level of host protection (mice with parasite recovery lower than control mice) while recombinant Ov-103 expressed in <italic toggle="yes">E. coli</italic> did not show significant protection. Interestingly, mice immunized with <italic toggle="yes">E. coli</italic> expressed recombinant Ov-RAL-2 induced a significantly higher protection than protein expressed in yeast (L3 survival reduction 39% vs. 24%, host protection 64% vs. 55%). These protection differences between proteins expressed in <italic toggle="yes">E. coli</italic> and yeast for both Ov-103 and Ov-RAL-2 seem not to relate to the serological IgG titers and molecular structures because both Ov-103 and Ov-RAL-2 expressed in <italic toggle="yes">E. coli</italic> and yeast displayed similar and comparable &#945;-helix structures and induced similar levels of IgG (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>). However, mice immunized with Ov-CPI-2M expressed in both <italic toggle="yes">E. coli</italic> and yeast produced similar protection against <italic toggle="yes">O. volvulus</italic> L3 challenge in the diffusion chamber (30% L3 survival reduction and 17% host protection) with similar levels of antigen-specific IgG levels (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>). To test for synergy of efficacy when the antigens are combined, fusion of Ov-103 and Ov-RAL-2 or Ov-103/Ov-RAL-2/Ov-CPI-2M was produced. The challenge test with the fusion revealed similar levels of protection induced by each individual protein, and there was no increased protective immunity observed in the antigen combination (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>).</p><p>Confirmatory protection with adjuvanted Bm-103 and Bm-RAL-2, the <italic toggle="yes">B. malayi</italic> homologues of Ov-103 and Ov-RAL-2, was determined using the gerbil model after challenge with <italic toggle="yes">B. malayi</italic> L3 larvae subcutaneously. Gerbils immunized with yeast-expressed recombinant Bm-103 or <italic toggle="yes">E. coli</italic>-expressed recombinant Bm-RAL-2 produced 39% and 42% early worm reduction 42 days post challenge with <italic toggle="yes">B. malayi</italic> L3 and 22% or 46% reduction of adult worm burden (150 days), respectively. Vaccination with a fusion Bm-103 + Bm-RAL-2 expressed in <italic toggle="yes">E. coli</italic> or with Bm-103 and Bm-RAL-2 co-administered separately resulted in improved efficacy with consistent and significant 49%&#8211;51% and 56%&#8211;61% worm reduction at 90 days postinfection, respectively, as compared to alum adjuvant control. Immunization with both antigens (fusion or concurrent) also significantly reduced the fecundity of female worms (<xref rid="B10" ref-type="bibr">Arumugam et&#160;al., 2016</xref>). Both Bm-103 and Bm-RAL-2 induced elevated levels of antigen-specific IgG. The Bm-CPI-2 in its native form did not induce worm reduction but instead caused the relocation of filarial worm to the heart and lung (<xref rid="B12" ref-type="bibr">Arumugam et&#160;al., 2014b</xref>). However, after the functional Asn66 was mutated to Lys66, the mutant form of Bm-CPI-2, Bm-CPI-2M, significantly reduced worm burden (48.0%) as well as fertility of the female worms 90 days post challenge with <italic toggle="yes">B. malayi</italic> L3. The anti-Bm-CPI-2M sera were able to induce the killing of <italic toggle="yes">B. malayi</italic> L3s <italic toggle="yes">in vitro</italic> in the presence of gerbil peritoneal exudate cells, suggesting antibody-dependent cell-mediated cytotoxicity as a putative protective mechanism (<xref rid="B11" ref-type="bibr">Arumugam et&#160;al., 2014a</xref>). The results in the <italic toggle="yes">B. malayi</italic>/gerbil model further supported the selection of Ov-RAL-2, Ov-103, and Ov-CPI-2M as the most promising vaccine candidates for onchocerciasis, and Bm-103, Bm-RAL-2, and Bm-CPI-2M as the vaccine candidates for lymphatic filariasis.</p></sec><sec id="s8"><title>The Leading Vaccine Candidates Ov-103 and Ov-RAL-2</title><p>Ov-103 and Ob-RAL-2 are down-selected as the leading vaccine candidates for onchocerciasis for further preclinical development. Based on the down-selection criteria highlighted above, these antigens exhibit the following properties: (i) immunodominant antigens recognized by putatively immune sera (<xref rid="B41" ref-type="bibr">Gallin et&#160;al., 1989</xref>, Lustigman et&#160;al., 1992); (ii) larval surface-associated antigens with immunological accessibility (<xref rid="B41" ref-type="bibr">Gallin et&#160;al., 1989</xref>, Lustigman et&#160;al., 1992); (iii) both antigens being immunogenic, inducing strong IgG responses in immunized mice; (iv) the significantly reduced L3 survival rate in mice immunized with recombinant Ov-103 and Ov-RAL-2 alone and in combination (<xref rid="B54" ref-type="bibr">Hess et&#160;al., 2014</xref>); (v) antibody inducing inhibition of L3 molting (<xref rid="B45" ref-type="bibr">George et&#160;al., 2019</xref>) or killing of nodular microfilariae <italic toggle="yes">in vitro</italic> (Lustigman et&#160;al., 1992); and (vi) protective homologues identified in other filaria (<xref rid="B99" ref-type="bibr">Pandiaraja et&#160;al., 2010</xref>; <xref rid="B10" ref-type="bibr">Arumugam et&#160;al., 2016</xref>), <italic toggle="yes">Ascaris</italic> (<xref rid="B126" ref-type="bibr">Wei et&#160;al., 2017</xref>), and hookworm (<xref rid="B135" ref-type="bibr">Zhan et&#160;al., 2004</xref>; <xref rid="B39" ref-type="bibr">Fujiwara et&#160;al., 2007</xref>).</p><p>Alum-formulated recombinant Ov-103 and Ov-RAL-2 induced significantly protective immunity against L3 challenge in diffusion chambers; however, the protective level remains partial and limited. To enhance the immunological responses and improve the protective immunity, recombinant Ov-103 and Ov-RAL-2 were formulated with different adjuvants that are approved for human use and known to induce dominant Th1, Th2, or combined Th1/Th2 responses including alum, Advax 1, Advax 2, CpG oligonucleotide (CpG), and MF59. Mice immunized with different adjuvant-formulated Ov-103 or Ov-RAL-2 individually or concurrently (combination) demonstrated different Th1/Th2 immune response profiles. Without adjuvant, recombinant Ov-103 and Ov-RAL-2 themselves did not induce any protective immunity. In the adjuvant groups, only alum-, Advax 2-, and MF59-formulated Ov-103 and Ov-RAL-2 induced significant protective immunity with similar levels of larval killing and host protection. The protection was associated with Th2-biased immune responses with IgG1 as the dominant antibody (<xref rid="B55" ref-type="bibr">Hess et&#160;al., 2016</xref>). Co-administration of Ov-103 and Ov-RAL-2 with the three adjuvants induced similar or even higher larval killing and host protection compared to mice receiving a single antigen. The highest level of larval killing was 47% achieved in mice immunized with two antigens formulated with Advax 2 as the adjuvant, suggesting that both antigens are not immunologically competitive and confer synergistic immune responses (<xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>). Based on chemokine profile and levels, more neutrophils and eosinophils were involved in the protective immune response induced by Ov-103, and more macrophage and neutrophil responses were involved in Ov-RAL-2-induced immune responses (<xref rid="B55" ref-type="bibr">Hess et&#160;al., 2016</xref>). Both recombinant Ov-103 and Ov-RAL-2 were very immunogenic and induced high levels of antigen-specific IgG without the induction of antigen-specific IgE responses. This is important as it may prevent the induction of an allergic reaction during immunization, which has hindered the continued vaccine development for Na-ASP-2, a potential vaccine candidate for hookworm infection that failed in clinical trial due to its ability to induce IgE in vaccinated people (<xref rid="B25" ref-type="bibr">Diemert et&#160;al., 2012</xref>).</p><p>The role of humoral immune responses in the protective immunity induced by immunization with Ov-103 or Ov-RAL-2 was confirmed in AID<sup>-/-</sup> mice that was deficient in producing IgG antibody. AID<sup>-/-</sup> mice immunized with Ov-103 or Ov-RAL-2 could not produce protection against challenge of <italic toggle="yes">O. volvulus</italic> L3. Further investigation on the IgG isotypes revealed that most people who lived in endemic areas and developed with putatively immune (86%) or concomitant immunity (95%) contained anti-Ov-103 and anti-Ov-RAL-2 cytophilic antibody responses (IgG1 and IgG3). Monospecific human anti-Ov-103 and anti-Ov-RAL-2 antibodies inhibited the molting of L3 when incubated with naive human monocytes (70%&#8211;80%) and to a lesser degree in the presence of na&#239;ve human neutrophils (46% for anti-Ov-103). Moreover, the inhibition of L3 molting with anti-Ov-103 antibodies was partially dependent on contact with the monocytes, while the inhibition of molting with anti-Ov-RAL-2 antibodies required the complete contact with the monocytes, suggesting that the mechanisms by which the two antibodies cause inhibition of molting are distinct. Notably, the L3 killing in Ov-103- and Ov-RAL-2-vaccinated mice only occurred when immune cells enter the chamber where the parasites reside, suggesting that ADCC is involved in the protective immunity induced by Ov-103 and Ov-RAL-2, and balanced Th1/Th2 responses are essential for the protective immunity to <italic toggle="yes">O. volvulus</italic> (<xref rid="B45" ref-type="bibr">George et&#160;al., 2019</xref>).</p><p>Before being advanced to clinical vaccine trials in humans, it was important to consider whether diverse host genetics may affect vaccine efficacy. Eight different genetically diverse collaborative cross recombinant inbred intercross mouse lines (CC-RIX) were immunized with both Ov-103 and Ov-RAL-2 formulated with the adjuvant Advax 2. After challenge, significant reductions in parasite survival were observed in 7 out of 8 tested CC-RIX lines with a similar level of protection as BALB/cByJ mice. However, there were no statistically significant correlations between larval killing and specific immune cell types, either with the levels of cytokines or chemokines measured in the chamber fluid and or in culture media of <italic toggle="yes">ex vivo</italic> antigen-stimulated spleen lymphocytes. Moreover, although immunization with both Ov-103 and Ov-RAL-2 induced antigen-specific IgG1 and IgG2a/b/c in BALB/cByJ and most of CC-RIX lines with different titers, there were no statistically significant correlations between antigen-specific antibody titer and the level of larval killing. These results reveal that the Ov-103 and Ov-RAL-2 vaccines are able to induce protection against <italic toggle="yes">Onchocerca</italic> L3 infection using varied mechanisms and in a wide range of host genetic backgrounds, suggesting that the vaccines could be translated for clinical development and may protect diverse human populations from infection with <italic toggle="yes">O. volvulus</italic> (<xref rid="B101" ref-type="bibr">Ryan et&#160;al., 2021</xref>).</p></sec><sec id="s9"><title>Preclinical Trial With Bivalent Adjuvanted Ov-103 and Ov-RAL-2 Vaccine in Cattle</title><p>In 2015, an international consortium including the Texas Children&#8217;s Center for Vaccine Development and its partners in US, Europe, and Africa launched The Onchocerciasis Vaccine for Africa Initiative (TOVA) with the goal of developing and evaluating an onchocerciasis vaccine for Africa (<xref rid="B59" ref-type="bibr">Hotez et&#160;al., 2015</xref>). Intense laboratory down-selection led to the selection of two antigens, Ov-103 and Ov-RAL-2, for further clinical development based on their consistent protective efficacies in mouse model studies. Although recombinant Ov-CPI-2M with functional Asn66 mutated to Lys66 induced a similar level of protection against <italic toggle="yes">O. volvulus</italic> L3 challenge, it was down-selected because of its ability to induce IgE responses in children &#8804;5 years of age. In comparison, there were no IgE responses found in Ov-RAL-2 and Ov-103 immunization (<xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>).</p><p>Currently, TOVA is moving forward to a preclinical trial in Cameroon for the immunogenicity and vaccine efficacy of co-administered Ov-RAL-2 and Ov-103 in cattle exposed to natural infection of <italic toggle="yes">O. ochengi</italic> (<xref rid="B91" ref-type="bibr">Makepeace et&#160;al., 2015</xref>). Due to the similarity of the life cycle transmitted by the same fly vector, overlapped endemic regions, and highly related vaccine candidates between <italic toggle="yes">O. volvulus</italic> in human and <italic toggle="yes">O. ochengi</italic> in cattle, the natural infection of cattle with <italic toggle="yes">O. ochengi</italic> in endemic areas is selected as the only one field vaccine trial model for validating the vaccine efficacy for human onchocerciasis (<xref rid="B93" ref-type="bibr">Makepeace and Tanya, 2016</xref>). Vaccination against onchocerciasis in natural host&#8211;parasite relationships represents the real-world vaccine efficacy in endemic regions. The data from the cattle trial in endemic regions will be translated to a phase I clinical trial in human. The target product profiles (TPPs) for developing an onchocerciasis vaccine for African living in endemic areas include the co-administration of Advax-2-adjuvanted Ov-103 and Ov-RAL-2 in children 1&#8211;5 years old (<xref rid="B59" ref-type="bibr">Hotez et&#160;al., 2015</xref>). However, a safety trial will be done in adults living in non-endemic and then in endemic regions to ensure that the vaccine is safe enough before it is tested in children. The aim of this vaccine is to prevent the establishment of infection in children before exposure to the infection. A serological investigation found that all 73 children 1&#8211;5 years old from a highly endemic region in Ghana did not show any anti-Ov-103 and Ov-RAL-2 IgE responses, while 3/27 and 1/27 of the children 6&#8211;8 years old displayed anti-Ov-103 or Ov-RAL-2 IgE responses, suggesting that continuous exposure to infective larvae in children over 5 years of age may develop IgE response to native Ov-103 and/or Ov-RAL-2 proteins during infection (<xref rid="B2" ref-type="bibr">Abraham et&#160;al., 2021</xref>). Therefore, the Ov-103 and Ov-RAL-2 vaccines should be safe for targeting children under 5 years of age without concern of pathological atopic responses as was other helminth vaccines when tested in humans (<xref rid="B51" ref-type="bibr">Hamilton et&#160;al., 2010</xref>; <xref rid="B25" ref-type="bibr">Diemert et&#160;al., 2012</xref>).</p></sec><sec sec-type="conclusions" id="s10"><title>Conclusions and Perspectives</title><p>After decades of unremitting efforts by researchers around the world, especially by the close collaboration among the New York Blood Center (Dr. Sara Lustigman), Thomas Jefferson University (Dr. David Abraham), and Texas Children&#8217;s Hospital Center for Vaccine Development (Dr. Peter Hotez and Maria Elena Bottazzi), two antigens Ov-103 and Ov-RAL-2 have been selected for a bivalent vaccine for clinical efficacy trials based on their consistent protective efficacy induced in mice. This bivalent vaccine has been moved forward to a clinical trial in naturally infected cattle in Cameroon with the exciting endorsement of TOVA. Efficacy results from the cattle clinical trial with adjuvanted bivalent Ov-103 and Ov-RAL-2 vaccines will provide critical information for their immunogenicity and protective efficacy on worm burden and patency under natural infection conditions. If their protective efficacy is confirmed in the cattle clinical trial, the first bivalent onchocerciasis vaccine with Advax-2- or alum-formulated bivalent Ov-103 and Ov-RAL-2 will be produced in large scale under cGMP conditions and used to perform a phase I safety clinical trial. The ultimate goal is to develop a vaccine that can be used safely in children under 5 years of age in endemic regions that prevents infection with <italic toggle="yes">O. volvulus</italic> and protects them from developing adult worm pathological consequences with time.</p><p>While we are testing our first generation of the onchocerciasis vaccine, the co-administration of recombinant Ov-103 and Ov-RAL-2 adjuvanted with Montanide&#8482; ISA 206VG in cattle in a preclinical trial in Africa, there still are some challenges. Notably, the protection rate of current selected Ov-103 and Ov-RAL-2 against <italic toggle="yes">Onchocerca</italic> L3 challenge is partial and limited despite the intensive search for the appropriate adjuvants and immunization regime to induce better protection. We will need to continue modeling whether the partial protection rate of current selected Ov-103 and Ov-RAL-2 against <italic toggle="yes">Onchocerca</italic> L3 challenge will be sufficient to support elimination (<xref rid="B118" ref-type="bibr">Turner et&#160;al., 2015</xref>). We also need to make more efforts to enhance their immunogenicity and vaccine efficacy by (i) searching and identifying the optimal adjuvant and formulation that might induce better protective immunity in humans; (ii) optimizing the co-administration of both antigens by making a fusion protein or combination of both individual antigens, to reach better protective efficacy; (iii) increasing efforts for the discovery of additional effective vaccine candidates, including new-generation vaccine antigens identified using new technologies such as functional genomics, transcriptomic, proteomic, secretomics, immunomics, and the mRNA vaccine technology; (iv) developing novel diagnostic assays that can support the rapid monitoring of vaccine efficacy in human clinical trials; (v) developing suitable product development strategies and the preferred target product profile; (vi) enhancing the collaboration between laboratory researchers and local health workers; (vii) promoting financial support from international organizations and/or governments to bring such a vaccine toward clinical trial and licensure; and (viii) advocating integration of such a vaccine with other elimination programs, including South-Sahara Africa government agencies in such efforts.</p></sec><sec sec-type="author-contributions" id="s11"><title>Author Contributions</title><p>BZ conceived and drafted the manuscript. SL, PH, and MB revised and added insight into the manuscript. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="funding-information" id="s12"><title>Funding</title><p>This work was supported by NIH/NIAID R01AI078314.</p></sec><sec sec-type="COI-statement" id="s13"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s14"><title>Publisher&#8217;s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are grateful to all researchers around the world that have consistently contributed to the onchocerciasis vaccine research field.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Wahab</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tuan</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1996</year>). <article-title>OvB20, an Onchocerca Volvulus-Cloned Antigen Selected by Differential Immunoscreening With Vaccination Serum in a Cattle Model of Onchocerciasis</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>76</volume> (<issue>1-2</issue>), <fpage>187</fpage>&#8211;<lpage>199</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(95)02558-8</pub-id><pub-id pub-id-type="pmid">8920006</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Graham-Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Development of a Recombinant Vaccine Against Human Onchocerciasis</article-title>. <source>Expert Rev. Vaccines</source><volume>20</volume>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14760584.2021.1977125</pub-id><pub-id pub-id-type="pmid">34488533</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>2001</year>). <article-title>Development of a Recombinant Antigen Vaccine Against Infection With the Filarial Worm Onchocerca Volvulus</article-title>. <source>Infect. Immun.</source><volume>69</volume> (<issue>1</issue>), <fpage>262</fpage>&#8211;<lpage>270</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.69.1.262-270.2001</pub-id><pub-id pub-id-type="pmid">11119514</pub-id><pub-id pub-id-type="pmcid">PMC97880</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schnyder-Candrian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Galioto</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Kerepesi</surname><given-names>L. A.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Immunoglobulin E and Eosinophil-Dependent Protective Immunity to Larval Onchocerca Volvulus in Mice Immunized With Irradiated Larvae</article-title>. <source>Infect. Immun.</source><volume>72</volume> (<issue>2</issue>), <fpage>810</fpage>&#8211;<lpage>817</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.72.2.810-817.2004</pub-id><pub-id pub-id-type="pmid">14742524</pub-id><pub-id pub-id-type="pmcid">PMC321619</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lucius</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trees</surname><given-names>A. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Immunity to Onchocerca Spp. In Animal Hosts</article-title>. <source>Trends Parasitol.</source><volume>18</volume> (<issue>4</issue>), <fpage>164</fpage>&#8211;<lpage>171</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1471-4922(02)02245-6</pub-id><pub-id pub-id-type="pmid">11998704</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaltmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rudin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marti</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lucius</surname><given-names>R.</given-names></name></person-group> (<year>1996</year>). <article-title>Identification of Chitinase as the Immunodominant Filarial Antigen Recognized by Sera of Vaccinated Rodents</article-title>. <source>J. Biol. Chem.</source><volume>271</volume> (<issue>3</issue>), <fpage>1441</fpage>&#8211;<lpage>1447</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.271.3.1441</pub-id><pub-id pub-id-type="pmid">8576136</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adegnika</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Zinsou</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Honkepehedji</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Dejon Agobe</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Vodonou</surname><given-names>K. G.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults: A Randomised, Controlled, Double-Blind, Phase 1 Dose-Escalation Trial</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume> (<issue>2</issue>), <fpage>275</fpage>&#8211;<lpage>285</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30288-7</pub-id><pub-id pub-id-type="pmid">32926834</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahumada</surname><given-names>V.</given-names></name><name name-style="western"><surname>Manotas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zakzuk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aglas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coronado</surname><given-names>S.</given-names></name><name name-style="western"><surname>Briza</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Identification and Physicochemical Characterization of a New Allergen From Ascaris Lumbricoides</article-title>. <source>Int. J. Mol. Sci.</source><volume>21</volume> (<issue>24</issue>), <fpage>9761</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21249761</pub-id><pub-id pub-id-type="pmcid">PMC7767342</pub-id><pub-id pub-id-type="pmid">33371317</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albiez</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Buttner</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Schulz-Key</surname><given-names>H.</given-names></name></person-group> (<year>1984</year>). <article-title>Studies on Nodules and Adult Onchocerca Volvulus During a Nodulectomy Trial in Hyperendemic Villages in Liberia and Upper Volta. II. Comparison of the Macrofilaria Population in Adult Nodule Carriers</article-title>. <source>Tropenmed. Parasitol.</source><volume>35</volume> (<issue>3</issue>), <fpage>163</fpage>&#8211;<lpage>166</lpage>.<pub-id pub-id-type="pmid">6541822</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M. E.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Vaccination of Gerbils With Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection Against Brugia Malayi Infection</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>10</volume> (<issue>4</issue>), <elocation-id>e0004586</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0004586</pub-id><pub-id pub-id-type="pmid">27045170</pub-id><pub-id pub-id-type="pmcid">PMC4821550</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2014</year>a). <article-title>Vaccination With a Genetically Modified Brugia Malayi Cysteine Protease Inhibitor-2 Reduces Adult Parasite Numbers and Affects the Fertility of Female Worms Following a Subcutaneous Challenge of Mongolian Gerbils (Meriones Unguiculatus) With B. Malayi Infective Larvae</article-title>. <source>Int. J. Parasitol.</source><volume>44</volume> (<issue>10</issue>), <fpage>675</fpage>&#8211;<lpage>679</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijpara.2014.05.003</pub-id><pub-id pub-id-type="pmid">24929131</pub-id><pub-id pub-id-type="pmcid">PMC5335902</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klei</surname><given-names>T. R.</given-names></name></person-group> (<year>2014</year>b). <article-title>Vaccination With Recombinant Brugia Malayi Cystatin Proteins Alters Worm Migration, Homing and Final Niche Selection Following a Subcutaneous Challenge of Mongolian Gerbils (Meriones Unguiculatus) With B. Malayi Infective Larvae</article-title>. <source>Parasit. Vectors</source><volume>7</volume>, <fpage>43</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1756-3305-7-43</pub-id><pub-id pub-id-type="pmid">24450869</pub-id><pub-id pub-id-type="pmcid">PMC3910689</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ash</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>J. M.</given-names></name></person-group> (<year>1970</year>). <article-title>Development of Subperiodic Brugia Malayi in the Jird, Meriones Unguiculatus, With Notes on Infections in Other Rodents</article-title>. <source>J. Parasitol.</source><volume>56</volume> (<issue>5</issue>), <fpage>969</fpage>&#8211;<lpage>973</lpage>. doi: <pub-id pub-id-type="doi">10.2307/3277515</pub-id><pub-id pub-id-type="pmid">5504534</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babayan</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>N.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Deletion of Parasite Immune Modulatory Sequences Combined With Immune Activating Signals Enhances Vaccine Mediated Protection Against Filarial Nematodes</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>6</volume> (<issue>12</issue>), <elocation-id>e1968</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0001968</pub-id><pub-id pub-id-type="pmid">23301106</pub-id><pub-id pub-id-type="pmcid">PMC3531514</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bah</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Schneckener</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hahnel</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Bayang</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Fieseler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmuck</surname><given-names>G. M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Emodepside Targets SLO-1 Channels of Onchocerca Ochengi and Induces Broad Anthelmintic Effects in a Bovine Model of Onchocerciasis</article-title>. <source>PloS Pathog.</source><volume>17</volume> (<issue>6</issue>), <elocation-id>e1009601</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1009601</pub-id><pub-id pub-id-type="pmid">34077488</pub-id><pub-id pub-id-type="pmcid">PMC8202924</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennuru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Grote</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harsha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Holroyd</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Stage-Specific Transcriptome and Proteome Analyses of the Filarial Parasite Onchocerca Volvulus and Its Wolbachia Endosymbiont</article-title>. <source>mBio</source><volume>7</volume> (<issue>6</issue>), <elocation-id>mBio.02028-16</elocation-id>. doi: <pub-id pub-id-type="doi">10.1128/mBio.02028-16</pub-id><pub-id pub-id-type="pmcid">PMC5137501</pub-id><pub-id pub-id-type="pmid">27881553</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bethony</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Parenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Desrosiers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuck</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>Randomized, Placebo-Controlled, Double-Blind Trial of the Na-ASP-2 Hookworm Vaccine in Unexposed Adults</article-title>. <source>Vaccine</source><volume>26</volume> (<issue>19</issue>), <fpage>2408</fpage>&#8211;<lpage>2417</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.02.049</pub-id><pub-id pub-id-type="pmid">18396361</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyer</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Eberhard</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Zea-Flores</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hightower</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pilcher</surname><given-names>J. B.</given-names></name><etal/></person-group>. (<year>1991</year>). <article-title>Guatemalan Human Onchocerciasis. II. Evidence for IgG3 Involvement in Acquired Immunity to Onchocerca Volvulus and Identification of Possible Immune-Associated Antigens</article-title>. <source>J. Immunol.</source><volume>146</volume> (<issue>11</issue>), <fpage>4001</fpage>&#8211;<lpage>4010</lpage>.<pub-id pub-id-type="pmid">2033268</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Tuan</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Shepley</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Tree</surname><given-names>T. I.</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Helm</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>1993</year>). <article-title>Onchocerca Volvulus: Characterization of an Immunodominant Hypodermal Antigen Present in Adult and Larval Parasites</article-title>. <source>Exp. Parasitol.</source><volume>77</volume> (<issue>4</issue>), <fpage>414</fpage>&#8211;<lpage>424</lpage>. doi: <pub-id pub-id-type="doi">10.1006/expr.1993.1101</pub-id><pub-id pub-id-type="pmid">8253155</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Unnasch</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Herring</surname><given-names>T. A.</given-names></name><etal/></person-group>. (<year>1996</year>). <article-title>Onchocerca Volvulus: Expression and Purification of Recombinant Antigen RAL2 - Studies on Immunogenicity and Pathogenicity</article-title>. <source>Biochem. Arch.</source><volume>12</volume>, <fpage>55</fpage>&#8211;<lpage>69</lpage>.</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho-Ngwa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>The Onchocerca Volvulus Cysteine Proteinase Inhibitor, Ov-CPI-2, Is a Target of Protective Antibody Response That Increases With Age</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>4</volume> (<issue>8</issue>), <elocation-id>e800</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0000800</pub-id><pub-id pub-id-type="pmid">20808763</pub-id><pub-id pub-id-type="pmcid">PMC2927424</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffeng</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Stolk</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Zoure</surname><given-names>H. G.</given-names></name><name name-style="western"><surname>Veerman</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Agblewonu</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Murdoch</surname><given-names>M. E.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>African Programme For Onchocerciasis Control 1995-2015: Model-Estimated Health Impact and Cost</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>7</volume> (<issue>1</issue>), <elocation-id>e2032</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0002032</pub-id><pub-id pub-id-type="pmid">23383355</pub-id><pub-id pub-id-type="pmcid">PMC3561133</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dadzie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Neira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Final Report of the Conference on the Eradicability of Onchocerciasis</article-title>. <source>Filaria J.</source><volume>2</volume> (<issue>1</issue>), <fpage>2</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1475-2883-2-2</pub-id><pub-id pub-id-type="pmid">12605722</pub-id><pub-id pub-id-type="pmcid">PMC150378</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de la Fuente</surname><given-names>J.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Vaccinomics: A Future Avenue for Vaccine Development Against Emerging Pathogens</article-title>. <source>Expert Rev. Vaccines</source><volume>20</volume> (<issue>12</issue>), <fpage>1561</fpage>&#8211;<lpage>1569</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14760584.2021.1987222</pub-id><pub-id pub-id-type="pmid">34582295</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diemert</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Freire</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jariwala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>R. G.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Generalized Urticaria Induced by the Na-ASP-2 Hookworm Vaccine: Implications for the Development of Vaccines Against Helminths</article-title>. <source>J. Allergy Clin. Immunol.</source><volume>130</volume> (<issue>1</issue>), <fpage>169</fpage>&#8211;<lpage>176 e166</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2012.04.027</pub-id><pub-id pub-id-type="pmid">22633322</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>The Epidemiology of Imported Acute Infectious Diseases in Zhejiang Province, China 2011-2016: Analysis of Surveillance Data</article-title>. <source>Am. J. Trop. Med. Hyg.</source><volume>98</volume> (<issue>3</issue>), <fpage>913</fpage>&#8211;<lpage>919</lpage>. doi: <pub-id pub-id-type="doi">10.4269/ajtmh.17-0284</pub-id><pub-id pub-id-type="pmid">29260651</pub-id><pub-id pub-id-type="pmcid">PMC5930882</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duke</surname><given-names>B. O.</given-names></name></person-group> (<year>1980</year>). <article-title>Observations on Onchocerca Volvulus in Experimentally Infected Chimpanzees</article-title>. <source>Tropenmed. Parasitol.</source><volume>31</volume> (<issue>1</issue>), <fpage>41</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="pmid">7376251</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duke</surname><given-names>B. O.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>P. J.</given-names></name></person-group> (<year>1968</year>). <article-title>The Contributions of Different Age Groups to the Transmission of Onchocerciasis in a Cameroon Forest Village</article-title>. <source>Trans. R. Soc. Trop. Med. Hyg.</source><volume>62</volume> (<issue>1</issue>), <fpage>22</fpage>&#8211;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0035-9203(68)90026-6</pub-id><pub-id pub-id-type="pmid">5639533</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberhard</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Zea-Flores</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>1991</year>). <article-title>Experimental Onchocerca Volvulus Infections in Mangabey Monkeys (Cercocebus Atys) Compared to Infections in Humans and Chimpanzees (Pan Troglodytes)</article-title>. <source>Am. J. Trop. Med. Hyg.</source><volume>44</volume> (<issue>2</issue>), <fpage>151</fpage>&#8211;<lpage>160</lpage>. doi: <pub-id pub-id-type="doi">10.4269/ajtmh.1991.44.151</pub-id><pub-id pub-id-type="pmid">2012258</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberhard</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Tsang</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Ottesen</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>1995</year>). <article-title>Onchocerca Volvulus: Parasitologic and Serologic Responses in Experimentally Infected Chimpanzees and Mangabey Monkeys</article-title>. <source>Exp. Parasitol.</source><volume>80</volume> (<issue>3</issue>), <fpage>454</fpage>&#8211;<lpage>462</lpage>. doi: <pub-id pub-id-type="doi">10.1006/expr.1995.1057</pub-id><pub-id pub-id-type="pmid">7729480</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brattig</surname><given-names>N. W.</given-names></name><name name-style="western"><surname>Trusch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schluter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Achukwi</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Eisenbarth</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Isolation, Identification and Functional Profile of Excretory-Secretory Peptides From Onchocerca Ochengi</article-title>. <source>Acta Trop.</source><volume>142</volume>, <fpage>156</fpage>&#8211;<lpage>166</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.actatropica.2014.11.015</pub-id><pub-id pub-id-type="pmid">25479441</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Janek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Niewienda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malecki</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>M. S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>A Helminth-Derived Chitinase Structurally Similar to Mammalian Chitinase Displays Immunomodulatory Properties in Inflammatory Lung Disease</article-title>. <source>J. Immunol. Res.</source><volume>2021</volume>, <fpage>6234836</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2021/6234836</pub-id><pub-id pub-id-type="pmid">34869783</pub-id><pub-id pub-id-type="pmcid">PMC8639245</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elson</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Calvopina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>W.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>R. H.</given-names></name><etal/></person-group>. (<year>1995</year>). <article-title>Immunity to Onchocerciasis: Putative Immune Persons Produce a Th1-Like Response to Onchocerca Volvulus</article-title>. <source>J. Infect. Dis.</source><volume>171</volume> (<issue>3</issue>), <fpage>652</fpage>&#8211;<lpage>658</lpage>. doi: <pub-id pub-id-type="doi">10.1093/infdis/171.3.652</pub-id><pub-id pub-id-type="pmid">7876612</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elson</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Days</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>T. B.</given-names></name></person-group> (<year>1994</year>). <article-title>Immunity to Onchocerciasis: Identification of a Putatively Immune Population in a Hyperendemic Area of Ecuador</article-title>. <source>J. Infect. Dis.</source><volume>169</volume> (<issue>3</issue>), <fpage>588</fpage>&#8211;<lpage>594</lpage>. doi: <pub-id pub-id-type="doi">10.1093/infdis/169.3.588</pub-id><pub-id pub-id-type="pmid">8158031</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Grieve</surname><given-names>R. B.</given-names></name></person-group> (<year>1996</year>). <article-title>Purification and Characterization of Three Larval Excretory-Secretory Proteins of Dirofilaria Immitis</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>75</volume> (<issue>2</issue>), <fpage>221</fpage>&#8211;<lpage>229</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(95)02533-2</pub-id><pub-id pub-id-type="pmid">8992320</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Grieve</surname><given-names>R. B.</given-names></name></person-group> (<year>1996</year>). <article-title>Molecular Cloning of a Developmentally Regulated Protein Isolated From Excretory-Secretory Products of Larval Dirofilaria Immitis</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>75</volume> (<issue>2</issue>), <fpage>231</fpage>&#8211;<lpage>240</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(95)02534-0</pub-id><pub-id pub-id-type="pmid">8992321</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>D. O.</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Ottesen</surname><given-names>E. A.</given-names></name></person-group> (<year>1989</year>). <article-title>Protective Immunity in Bancroftian Filariasis. Selective Recognition of a 43-kD Larval Stage Antigen by Infection-Free Individuals in an Endemic Area</article-title>. <source>J. Clin. Invest.</source><volume>83</volume> (<issue>1</issue>), <fpage>14</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">2642916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI113850</pub-id><pub-id pub-id-type="pmcid">PMC303637</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuhrman</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Piessens</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Perler</surname><given-names>F. B.</given-names></name></person-group> (<year>1992</year>). <article-title>Transmission-Blocking Antibodies Recognize Microfilarial Chitinase in Brugian Lymphatic Filariasis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>89</volume> (<issue>5</issue>), <fpage>1548</fpage>&#8211;<lpage>1552</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.89.5.1548</pub-id><pub-id pub-id-type="pmid">1542646</pub-id><pub-id pub-id-type="pmcid">PMC48489</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mendez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loukas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Reduction of Worm Fecundity and Canine Host Blood Loss Mediates Protection Against Hookworm Infection Elicited by Vaccination With Recombinant Ac-16</article-title>. <source>Clin. Vaccine Immunol.</source><volume>14</volume> (<issue>3</issue>), <fpage>281</fpage>&#8211;<lpage>287</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CVI.00404-06</pub-id><pub-id pub-id-type="pmid">17267592</pub-id><pub-id pub-id-type="pmcid">PMC1828853</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ellner</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Erttmann</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>White</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Newland</surname><given-names>H. S.</given-names></name><etal/></person-group>. (<year>1988</year>). <article-title>Cell-Mediated Immune Responses in Human Infection With Onchocerca Volvulus</article-title>. <source>J. Immunol.</source><volume>140</volume> (<issue>6</issue>), <fpage>1999</fpage>&#8211;<lpage>2007</lpage>.<pub-id pub-id-type="pmid">3257994</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallin</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kron</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Rechnitzer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Newland</surname><given-names>H. S.</given-names></name><etal/></person-group>. (<year>1989</year>). <article-title>Onchocerca Volvulus Recombinant Antigen: Physical Characterization and Clinical Correlates With Serum Reactivity</article-title>. <source>J. Infect. Dis.</source><volume>160</volume> (<issue>3</issue>), <fpage>521</fpage>&#8211;<lpage>529</lpage>. doi: <pub-id pub-id-type="doi">10.1093/infdis/160.3.521</pub-id><pub-id pub-id-type="pmid">2760503</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Mayoral</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Trevino</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Perez-Pinar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Knaute</surname><given-names>T.</given-names></name><name name-style="western"><surname>Umpierrez</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Relationships Between IgE/IgG4 Epitopes, Structure and Function in Anisakis Simplex Ani s 5, a Member of the SXP/RAL-2 Protein Family</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>8</volume> (<issue>3</issue>), <elocation-id>e2735</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0002735</pub-id><pub-id pub-id-type="pmid">24603892</pub-id><pub-id pub-id-type="pmcid">PMC3945735</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gardon-Wendel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Demanga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kamgno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chippaux</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Boussinesq</surname><given-names>M.</given-names></name></person-group> (<year>1997</year>). <article-title>Serious Reactions After Mass Treatment of Onchocerciasis With Ivermectin in an Area Endemic for Loa Infection</article-title>. <source>Lancet</source><volume>350</volume> (<issue>9070</issue>), <fpage>18</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">9217715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(96)11094-1</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>G. B. D. Disease Injury Incidence and Prevalence Collaborators</collab></person-group> (<year>2018</year>). <article-title>Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017</article-title>. <source>Lancet</source><volume>392</volume> (<issue>10159</issue>), <fpage>1789</fpage>&#8211;<lpage>1858</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmid">30496104</pub-id><pub-id pub-id-type="pmcid">PMC6227754</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tricoche</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Antibody Responses Against the Vaccine Antigens Ov-103 and Ov-RAL-2 Are Associated With Protective Immunity to Onchocerca Volvulus Infection in Both Mice and Humans</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>13</volume> (<issue>9</issue>), <elocation-id>e0007730</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0007730</pub-id><pub-id pub-id-type="pmid">31525197</pub-id><pub-id pub-id-type="pmcid">PMC6762197</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Henkle-Duehrsen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Unnasch</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>1999</year>). <article-title>Patterns of Onchocerca Volvulus Recombinant Antigen Recognition in a Bovine Model of Onchocerciasis</article-title>. <source>Parasitology</source><volume>119</volume> (<issue> Pt 6</issue>), <fpage>603</fpage>&#8211;<lpage>612</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0031182099005065</pub-id><pub-id pub-id-type="pmid">10633922</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Gbakima</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Albiez</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>H. R.</given-names></name></person-group> (<year>1985</year>). <article-title>Humoral and Cellular Immune Responses to Onchocerca Volvulus Infection in Humans</article-title>. <source>Rev. Infect. Dis.</source><volume>7</volume> (<issue>6</issue>), <fpage>789</fpage>&#8211;<lpage>795</lpage>. doi: <pub-id pub-id-type="doi">10.1093/clinids/7.6.789</pub-id><pub-id pub-id-type="pmid">4070916</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Atmadja</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>R. M.</given-names></name></person-group> (<year>2000</year>). <article-title>The Abundant Larval Transcript-1 and -2 Genes of Brugia Malayi Encode Stage-Specific Candidate Vaccine Antigens for Filariasis</article-title>. <source>Infect. Immun.</source><volume>68</volume> (<issue>7</issue>), <fpage>4174</fpage>&#8211;<lpage>4179</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.68.7.4174-4179.2000</pub-id><pub-id pub-id-type="pmid">10858234</pub-id><pub-id pub-id-type="pmcid">PMC101719</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Blaxter</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>R. M.</given-names></name></person-group> (<year>1997</year>). <article-title>Differentially Expressed, Abundant Trans-Spliced cDNAs From Larval Brugia Malayi</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>87</volume> (<issue>1</issue>), <fpage>85</fpage>&#8211;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0166-6851(97)00050-9</pub-id><pub-id pub-id-type="pmid">9233676</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregory</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>R. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Cystatins From Filarial Parasites: Evolution, Adaptation and Function in the Host-Parasite Relationship</article-title>. <source>Int. J. Biochem. Cell Biol.</source><volume>40</volume> (<issue>6-7</issue>), <fpage>1389</fpage>&#8211;<lpage>1398</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biocel.2007.11.012</pub-id><pub-id pub-id-type="pmid">18249028</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>MacGlashan</surname><given-names>D. W.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Saini</surname><given-names>S. S.</given-names></name></person-group> (<year>2010</year>). <article-title>IgE Antibody-Specific Activity in Human Allergic Disease</article-title>. <source>Immunol. Res.</source><volume>47</volume> (<issue>1-3</issue>), <fpage>273</fpage>&#8211;<lpage>284</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12026-009-8160-3</pub-id><pub-id pub-id-type="pmid">20066506</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Egerton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1999</year>). <article-title>DNA Immunisation With Onchocerca Volvulus Chitinase Induces Partial Protection Against Challenge Infection With L3 Larvae in Mice</article-title>. <source>Vaccine</source><volume>18</volume> (<issue>7-8</issue>), <fpage>647</fpage>&#8211;<lpage>655</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0264-410X(99)00274-1</pub-id><pub-id pub-id-type="pmid">10547424</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kyewski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sonnenburg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lucius</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>A Filarial Cysteine Protease Inhibitor Down-Regulates T Cell Proliferation and Enhances Interleukin-10 Production</article-title>. <source>Eur. J. Immunol.</source><volume>27</volume> (<issue>9</issue>), <fpage>2253</fpage>&#8211;<lpage>2260</lpage>. doi: <pub-id pub-id-type="doi">10.1002/eji.1830270920</pub-id><pub-id pub-id-type="pmid">9341767</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bonne-Annee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deckman</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P. J.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Vaccines to Combat River Blindness: Expression, Selection and Formulation of Vaccines Against Infection With Onchocerca Volvulus in a Mouse Model</article-title>. <source>Int. J. Parasitol.</source><volume>44</volume> (<issue>9</issue>), <fpage>637</fpage>&#8211;<lpage>646</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijpara.2014.04.006</pub-id><pub-id pub-id-type="pmid">24907553</pub-id><pub-id pub-id-type="pmcid">PMC4118642</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Torigian</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>The Immunomodulatory Role of Adjuvants in Vaccines Formulated With the Recombinant Antigens Ov-103 and Ov-RAL-2 Against Onchocerca Volvulus in Mice</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>10</volume> (<issue>7</issue>), <elocation-id>e0004797</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0004797</pub-id><pub-id pub-id-type="pmid">27387453</pub-id><pub-id pub-id-type="pmcid">PMC4936747</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Sequence Analysis of Bs-Ag2 Gene From Baylisascaris Schroederi of Giant Panda and Evaluation of the Efficacy of a Recombinant Bs-Ag2 Antigen in Mice</article-title>. <source>Vaccine</source><volume>27</volume> (<issue>22</issue>), <fpage>3007</fpage>&#8211;<lpage>3011</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.077</pub-id><pub-id pub-id-type="pmid">19428912</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoch</surname><given-names>B.</given-names></name><name name-style="western"><surname>W</surname><given-names>G.</given-names></name><name name-style="western"><surname>Enyong</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#252;der</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Harnett</surname><given-names>W.</given-names></name><name name-style="western"><surname>Renz</surname><given-names>A.</given-names></name></person-group> (<year>1992</year>). <article-title>Serological Recognition of Specific and Crossreactive of O. Ochengi and O. Volvulus by Infected Cattle and Humans</article-title>. <source>Trop. Med. Parasitol.</source><volume>43</volume>, <fpage>206</fpage>&#8211;<lpage>207</lpage>.</mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Beaumier</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hayward</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Advancing a Vaccine to Prevent Hookworm Disease and Anemia</article-title>. <source>Vaccine</source><volume>34</volume> (<issue>26</issue>), <fpage>3001</fpage>&#8211;<lpage>3005</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.078</pub-id><pub-id pub-id-type="pmid">27040400</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Klei</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>The Onchocerciasis Vaccine for Africa&#8211;TOVA&#8211;Initiative</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>9</volume> (<issue>1</issue>), <elocation-id>e0003422</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0003422</pub-id><pub-id pub-id-type="pmid">25634641</pub-id><pub-id pub-id-type="pmcid">PMC4310604</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Institute for Health Metrics and Evaluation</collab></person-group><source>GBD Summaries. Onchocerciasis &#8212; Level 3 Cause</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.healthdata.org/results/gbd_summaries/2019/onchocerciasis-level-3-cause">https://www.healthdata.org/results/gbd_summaries/2019/onchocerciasis-level-3-cause</uri>.</mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>1994</year>). <article-title>Identification and Characterization of an Onchocerca Volvulus cDNA Clone Encoding a Highly Immunogenic Calponin-Like Protein</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>65</volume> (<issue>1</issue>), <fpage>135</fpage>&#8211;<lpage>146</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(94)90122-8</pub-id><pub-id pub-id-type="pmid">7935620</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>1997</year>). <article-title>Identification of Larval-Stage-Specific Antigens of Onchocerca Volvulus Uniquely Recognized by Putative Immune Sera From Humans and Vaccination Sera From Animal Models</article-title>. <source>Ann. Trop. Med. Parasitol.</source><volume>91</volume> (<issue>1</issue>), <fpage>67</fpage>&#8211;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1080/00034983.1997.11813113</pub-id><pub-id pub-id-type="pmid">9093431</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>George</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Koussa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parkhouse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>S. E.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>The Parasite-Derived rOv-ASP-1 Is an Effective Antigen-Sparing CD4(+) T Cell-Dependent Adjuvant for the Trivalent Inactivated Influenza Vaccine, and Functions in the Absence of MyD88 Pathway</article-title>. <source>Vaccine</source><volume>36</volume> (<issue>25</issue>), <fpage>3650</fpage>&#8211;<lpage>3665</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.05.029</pub-id><pub-id pub-id-type="pmid">29764680</pub-id><pub-id pub-id-type="pmcid">PMC6595497</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Gilvary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1996</year>). <article-title>Characterization of a Secreted Antigen of Onchocerca Volvulus With Host-Protective Potential</article-title>. <source>Parasite Immunol.</source><volume>18</volume> (<issue>1</issue>), <fpage>29</fpage>&#8211;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-3024.1996.d01-10.x</pub-id><pub-id pub-id-type="pmid">9223154</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Gilvary</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Tropomyosin Implicated in Host Protective Responses to Microfilariae in Onchocerciasis</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>95</volume> (<issue>13</issue>), <fpage>7550</fpage>&#8211;<lpage>7555</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.95.13.7550</pub-id><pub-id pub-id-type="pmid">9636187</pub-id><pub-id pub-id-type="pmcid">PMC22680</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Concannon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murasko</surname><given-names>D. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Enhanced Humoral Response to Influenza Vaccine in Aged Mice With a Novel Adjuvant, rOv-ASP-1</article-title>. <source>Vaccine</source><volume>34</volume> (<issue>7</issue>), <fpage>887</fpage>&#8211;<lpage>892</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.003</pub-id><pub-id pub-id-type="pmid">26795365</pub-id><pub-id pub-id-type="pmcid">PMC4731280</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kass</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abdullai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name><etal/></person-group>. (<year>1994</year>). <article-title>Onchocerca Volvulus: <italic toggle="yes">In Vitro</italic> Cytotoxic Effects of Human Neutrophils and Serum on Third-Stage Larvae</article-title>. <source>Trop. Med. Parasitol.</source><volume>45</volume> (<issue>4</issue>), <fpage>331</fpage>&#8211;<lpage>335</lpage>.<pub-id pub-id-type="pmid">7716398</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brotman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Onchocerca Volvulus: <italic toggle="yes">In Vitro</italic> Killing of Microfilaria by Neutrophils and Eosinophils From Experimentally Infected Chimpanzees</article-title>. <source>Trop. Med. Parasitol.</source><volume>42</volume> (<issue>4</issue>), <fpage>351</fpage>&#8211;<lpage>355</lpage>.<pub-id pub-id-type="pmid">1796232</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kass</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name></person-group> (<year>1995</year>). <article-title>Onchocerca Volvulus: A Comparative Study of <italic toggle="yes">In Vitro</italic> Neutrophil Killing of Microfilariae and Humoral Responses in Infected and Endemic Normals</article-title>. <source>Exp. Parasitol.</source><volume>81</volume> (<issue>1</issue>), <fpage>9</fpage>&#8211;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1006/expr.1995.1087</pub-id><pub-id pub-id-type="pmid">7628571</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Schynder-Candrian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rajan</surname><given-names>T. V.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>F. K.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name></person-group> (<year>1998</year>). <article-title>Immune Responses to Third Stage Larvae of Onchocerca Volvulus in Interferon-Gamma and Interleukin-4 Knockout Mice</article-title>. <source>Parasite Immunol.</source><volume>20</volume> (<issue>7</issue>), <fpage>319</fpage>&#8211;<lpage>324</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-3024.1998.00148.x</pub-id><pub-id pub-id-type="pmid">9717193</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>G. T.</given-names></name><name name-style="western"><surname>Huima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>1998</year>). <article-title>Characterization of an Onchocerca Volvulus L3-Specific Larval Antigen, Ov-ALT-1</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>96</volume> (<issue>1-2</issue>), <fpage>177</fpage>&#8211;<lpage>183</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0166-6851(98)00094-2</pub-id><pub-id pub-id-type="pmid">9851616</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanampalliwar</surname><given-names>A. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Reverse Vaccinology and Its Applications</article-title>. <source>Methods Mol. Biol.</source><volume>2131</volume>, <fpage>1</fpage>&#8211;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-0716-0389-5_1</pub-id><pub-id pub-id-type="pmid">32162247</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly-Hope</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Cano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Bockarie</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Molyneux</surname><given-names>D. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Innovative Tools for Assessing Risks for Severe Adverse Events in Areas of Overlapping Loa and Other Filarial Distributions: The Application of Micro-Stratification Mapping</article-title>. <source>Parasit. Vectors</source><volume>7</volume>, <fpage>307</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1756-3305-7-307</pub-id><pub-id pub-id-type="pmid">24992829</pub-id><pub-id pub-id-type="pmcid">PMC4101798</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Garside</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Goodrick</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brass</surname><given-names>A.</given-names></name><name name-style="western"><surname>Price</surname><given-names>N. C.</given-names></name><etal/></person-group>. (<year>1997</year>). <article-title>The Ov20 Protein of the Parasitic Nematode Onchocerca Volvulus. A Structurally Novel Class of Small Helix-Rich Retinol-Binding Proteins</article-title>. <source>J. Biol. Chem.</source><volume>272</volume> (<issue>47</issue>), <fpage>29442</fpage>&#8211;<lpage>29448</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.272.47.29442</pub-id><pub-id pub-id-type="pmid">9368002</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagatie</surname><given-names>O.</given-names></name><name name-style="western"><surname>Verheyen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Dorst</surname><given-names>B.</given-names></name><name name-style="western"><surname>Batsa Debrah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Debrah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stuyver</surname><given-names>L. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Linear Epitopes in Onchocerca Volvulus Vaccine Candidate Proteins and Excretory-Secretory Proteins</article-title>. <source>Parasite Immunol.</source><volume>40</volume> (<issue>11</issue>), <elocation-id>e12587</elocation-id>. doi: <pub-id pub-id-type="doi">10.1111/pim.12587</pub-id><pub-id pub-id-type="pmid">30188578</pub-id><pub-id pub-id-type="pmcid">PMC6220944</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lange</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Yutanawiboonchai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lok</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Trpis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name></person-group> (<year>1993</year>). <article-title>Induction of Protective Immunity Against Larval Onchocerca Volvulus in a Mouse Model</article-title>. <source>Am. J. Trop. Med. Hyg.</source><volume>49</volume> (<issue>6</issue>), <fpage>783</fpage>&#8211;<lpage>788</lpage>. doi: <pub-id pub-id-type="doi">10.4269/ajtmh.1993.49.783</pub-id><pub-id pub-id-type="pmid">8279644</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lange</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Yutanawiboonchai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name></person-group> (<year>1994</year>). <article-title>IL-4- and IL-5-Dependent Protective Immunity to Onchocerca Volvulus Infective Larvae in BALB/cBYJ Mice</article-title>. <source>J. Immunol.</source><volume>153</volume> (<issue>1</issue>), <fpage>205</fpage>&#8211;<lpage>211</lpage>.<pub-id pub-id-type="pmid">8207236</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leke</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Boto</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Lando</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ngu</surname><given-names>J. L.</given-names></name></person-group> (<year>1989</year>). <article-title>Immunity to Onchocerca Volvulus. Serum Mediated Leucocyte Adherence to Infective Larvae <italic toggle="yes">In Vitro</italic>
</article-title>. <source>Trop. Med. Parasitol.</source><volume>40</volume> (<issue>1</issue>), <fpage>39</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">2740726</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lizotte-Waniewski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tawe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guiliano</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S. A.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Identification of Potential Vaccine and Drug Target Candidates by Expressed Sequence Tag Analysis and Immunoscreening of Onchocerca Volvulus Larval cDNA Libraries</article-title>. <source>Infect. Immun.</source><volume>68</volume> (<issue>6</issue>), <fpage>3491</fpage>&#8211;<lpage>3501</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.68.6.3491-3501.2000</pub-id><pub-id pub-id-type="pmid">10816503</pub-id><pub-id pub-id-type="pmcid">PMC97634</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Developing a Vaccine to Accelerate Onchocerciasis Elimination</article-title>. <source>Trends Parasitol.</source><volume>34</volume> (<issue>1</issue>), <fpage>1</fpage>&#8211;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pt.2017.11.001</pub-id><pub-id pub-id-type="pmid">29174373</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brotman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Characterization of an Onchocerca Volvulus cDNA Clone Encoding a Genus Specific Antigen Present in Infective Larvae and Adult Worms</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>45</volume> (<issue>1</issue>), <fpage>65</fpage>&#8211;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(91)90028-5</pub-id><pub-id pub-id-type="pmid">2052041</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brotman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>McKerrow</surname><given-names>J. H.</given-names></name></person-group> (<year>1992</year>a). <article-title>Molecular Cloning and Characterization of Onchocystatin, a Cysteine Proteinase Inhibitor of Onchocerca Volvulus</article-title>. <source>J. Biol. Chem.</source><volume>267</volume> (<issue>24</issue>), <fpage>17339</fpage>&#8211;<lpage>17346</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(18)41931-X</pub-id><pub-id pub-id-type="pmid">1512269</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brotman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Huima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A. M.</given-names></name></person-group> (<year>1992</year>b). <article-title>Identification and Characterization of an Onchocerca Volvulus cDNA Clone Encoding a Microfilarial Surface-Associated Antigen</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>50</volume> (<issue>1</issue>), <fpage>79</fpage>&#8211;<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(92)90246-G</pub-id><pub-id pub-id-type="pmid">1542318</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>James</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Tawe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name></person-group> (<year>2002</year>). <article-title>Towards a Recombinant Antigen Vaccine Against Onchocerca Volvulus</article-title>. <source>Trends Parasitol.</source><volume>18</volume> (<issue>3</issue>), <fpage>135</fpage>&#8211;<lpage>141</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1471-4922(01)02211-5</pub-id><pub-id pub-id-type="pmid">11854092</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>CD4+-Dependent Immunity to Onchocerca Volvulus Third-Stage Larvae in Humans and the Mouse Vaccination Model: Common Ground and Distinctions</article-title>. <source>Int. J. Parasitol.</source><volume>33</volume> (<issue>11</issue>), <fpage>1161</fpage>&#8211;<lpage>1171</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0020-7519(03)00170-X</pub-id><pub-id pub-id-type="pmid">13678632</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Klei</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Babayan</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Onchocerca Volvulus: The Road From Basic Biology to a Vaccine</article-title>. <source>Trends Parasitol</source>., <fpage>64</fpage>&#8211;<lpage>79</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pt.2017.08.011</pub-id><pub-id pub-id-type="pmid">28958602</pub-id><pub-id pub-id-type="pmcid">PMC5748257</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>McCarter</surname><given-names>J. P.</given-names></name></person-group> (<year>2007</year>). <article-title>Ivermectin Resistance in Onchocerca Volvulus: Toward a Genetic Basis</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>1</volume> (<issue>1</issue>), <elocation-id>e76</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0000076</pub-id><pub-id pub-id-type="pmid">17989789</pub-id><pub-id pub-id-type="pmcid">PMC2041823</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>rOv-ASP-1, a Recombinant Secreted Protein of the Helminth Onchocercavolvulus, Is a Potent Adjuvant for Inducing Antibodies to Ovalbumin, HIV-1 Polypeptide and SARS-CoV Peptide Antigens</article-title>. <source>Vaccine</source><volume>23</volume> (<issue>26</issue>), <fpage>3446</fpage>&#8211;<lpage>3452</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.098</pub-id><pub-id pub-id-type="pmid">15837368</pub-id><pub-id pub-id-type="pmcid">PMC7115491</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Tawe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oksov</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Ov-ASP-1, the Onchocerca Volvulus Homologue of the Activation Associated Secreted Protein Family Is Immunostimulatory and Can Induce Protective Anti-Larval Immunity</article-title>. <source>Parasite Immunol.</source><volume>26</volume> (<issue>1</issue>), <fpage>53</fpage>&#8211;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.0141-9838.2004.00685.x</pub-id><pub-id pub-id-type="pmid">15198646</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Turaga</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Harmon-Brown</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>M. C.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Differential Cytokine and Antibody Responses to Adult and Larval Stages of Onchocerca Volvulus Consistent With the Development of Concomitant Immunity</article-title>. <source>Infect. Immun.</source><volume>70</volume> (<issue>6</issue>), <fpage>2796</fpage>&#8211;<lpage>2804</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.70.6.2796-2804.2002</pub-id><pub-id pub-id-type="pmid">12010965</pub-id><pub-id pub-id-type="pmcid">PMC127981</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Babayan</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D. W.</given-names></name></person-group> (<year>2015</year>). <article-title>The Case for Vaccine Development in the Strategy to Eradicate River Blindness (Onchocerciasis) From Africa</article-title>. <source>Expert Rev. Vaccines</source><volume>14</volume> (<issue>9</issue>), <fpage>1163</fpage>&#8211;<lpage>1165</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14760584.2015.1059281</pub-id><pub-id pub-id-type="pmid">26091691</pub-id><pub-id pub-id-type="pmcid">PMC11148793</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Laney</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Nfon</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Njongmeta</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Tanya</surname><given-names>V. N.</given-names></name><etal/></person-group>. (<year>2009</year>). <article-title>Immunisation With a Multivalent, Subunit Vaccine Reduces Patent Infection in a Natural Bovine Model of Onchocerciasis During Intense Field Exposure</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>3</volume> (<issue>11</issue>), <elocation-id>e544</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0000544</pub-id><pub-id pub-id-type="pmid">19901988</pub-id><pub-id pub-id-type="pmcid">PMC2770122</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Tanya</surname><given-names>V. N.</given-names></name></person-group> (<year>2016</year>). <article-title>25 Years of the Onchocerca Ochengi Model</article-title>. <source>Trends Parasitol.</source><volume>32</volume> (<issue>12</issue>), <fpage>966</fpage>&#8211;<lpage>978</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pt.2016.08.013</pub-id><pub-id pub-id-type="pmid">27665524</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Wieseman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tropea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaslow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Onchocerca Volvulus Glycolytic Enzyme Fructose-1,6-Bisphosphate Aldolase as a Target for a Protective Immune Response in Humans</article-title>. <source>Infect. Immun.</source><volume>70</volume> (<issue>2</issue>), <fpage>851</fpage>&#8211;<lpage>858</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.70.2.851-858.2002</pub-id><pub-id pub-id-type="pmid">11796620</pub-id><pub-id pub-id-type="pmcid">PMC127653</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKeand</surname><given-names>J. B.</given-names></name></person-group> (<year>2000</year>). <article-title>Vaccine Development and Diagnostics of Dictyocaulus Viviparus</article-title>. <source>Parasitology</source><volume>120 Suppl</volume>, <fpage>S17</fpage>&#8211;<lpage>S23</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0031182099005727</pub-id><pub-id pub-id-type="pmid">10874707</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McSorley</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Hewitson</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Maizels</surname><given-names>R. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Immunomodulation by Helminth Parasites: Defining Mechanisms and Mediators</article-title>. <source>Int. J. Parasitol.</source><volume>43</volume> (<issue>3-4</issue>), <fpage>301</fpage>&#8211;<lpage>310</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijpara.2012.11.011</pub-id><pub-id pub-id-type="pmid">23291463</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>G. F.</given-names></name></person-group> (<year>1990</year>). <article-title>A Note on Concomitant Immunity in Host-Parasite Relationships: A Successfully Transplanted Concept From Tumor Immunology</article-title>. <source>Adv. Cancer Res.</source><volume>54</volume>, <fpage>319</fpage>&#8211;<lpage>332</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0065-230X(08)60816-7</pub-id><pub-id pub-id-type="pmid">2105004</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>H.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Mitre</surname><given-names>E.</given-names></name></person-group> (<year>2013</year>). <article-title>A Comprehensive, Model-Based Review of Vaccine and Repeat Infection Trials for Filariasis</article-title>. <source>Clin. Microbiol. Rev.</source><volume>26</volume> (<issue>3</issue>), <fpage>381</fpage>&#8211;<lpage>421</lpage>. doi: <pub-id pub-id-type="doi">10.1128/CMR.00002-13</pub-id><pub-id pub-id-type="pmid">23824365</pub-id><pub-id pub-id-type="pmcid">PMC3719488</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandiaraja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Murugan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hoti</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Kaliraj</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Molecular Characterization of a Truncated Antigen (Wb14) of SXP-1 of Wuchereria Bancrofti From Four Endemic Regions in India</article-title>. <source>Exp. Parasitol.</source><volume>125</volume> (<issue>3</issue>), <fpage>236</fpage>&#8211;<lpage>243</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.exppara.2010.01.027</pub-id><pub-id pub-id-type="pmid">20138869</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romo</surname><given-names>M. L.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel Evidence to Motivate Onchocerciasis Elimination</article-title>. <source>Lancet Infect. Dis.</source><volume>20</volume> (<issue>11</issue>), <fpage>1223</fpage>&#8211;<lpage>1224</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30284-X</pub-id><pub-id pub-id-type="pmid">32598870</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>de Villena</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Leiby</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Onchocerca Volvulus Bivalent Subunit Vaccine Induces Protective Immunity in Genetically Diverse Collaborative Cross Recombinant Inbred Intercross Mice</article-title>. <source>NPJ Vaccines</source><volume>6</volume> (<issue>1</issue>), <fpage>17</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41541-020-00276-2</pub-id><pub-id pub-id-type="pmid">33500417</pub-id><pub-id pub-id-type="pmcid">PMC7838260</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jariwala</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Periago</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Gazzinelli</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P. J.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>A History of Hookworm Vaccine Development</article-title>. <source>Hum. Vaccin.</source><volume>7</volume> (<issue>11</issue>), <fpage>1234</fpage>&#8211;<lpage>1244</lpage>. doi: <pub-id pub-id-type="doi">10.4161/hv.7.11.18443</pub-id><pub-id pub-id-type="pmid">22064562</pub-id><pub-id pub-id-type="pmcid">PMC3323499</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schonemeyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lucius</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sonnenburg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brattig</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sabat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Modulation of Human T Cell Responses and Macrophage Functions by Onchocystatin, a Secreted Protein of the Filarial Nematode Onchocerca Volvulus</article-title>. <source>J. Immunol.</source><volume>167</volume> (<issue>6</issue>), <fpage>3207</fpage>&#8211;<lpage>3215</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.167.6.3207</pub-id><pub-id pub-id-type="pmid">11544307</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Al-Qubati</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zieleniewski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kapila</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Onchocerciasis (River Blindness): Larva-Induced Eczema (Onchodermatitis) From an Important Oculocutaneous Tropical Disease Spilling Over Into North America and Europe</article-title>. <source>Int. J. Dermatol.</source><volume>59</volume> (<issue>9</issue>), <fpage>1065</fpage>&#8211;<lpage>1070</lpage>. doi: <pub-id pub-id-type="doi">10.1111/ijd.14614</pub-id><pub-id pub-id-type="pmid">31513297</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shey</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Ghogomu</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Shintouo</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Nkemngo</surname><given-names>F. N.</given-names></name><name name-style="western"><surname>Nebangwa</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Esoh</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate Against Onchocerciasis and Related Filarial Diseases</article-title>. <source>Pathogens</source><volume>10</volume> (<issue>2</issue>), <fpage>99</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens10020099</pub-id><pub-id pub-id-type="pmid">33494344</pub-id><pub-id pub-id-type="pmcid">PMC7912539</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steves</surname><given-names>F. E.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Hein</surname><given-names>V. D.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>T. A.</given-names></name></person-group> (<year>1973</year>). <article-title>Efficacy of a Hookworm (Ancylostoma Caninum) Vaccine for Dogs</article-title>. <source>J. Am. Vet. Med. Assoc.</source><volume>163</volume> (<issue>3</issue>), <fpage>231</fpage>&#8211;<lpage>235</lpage>.<pub-id pub-id-type="pmid">4721752</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Elson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>J. E.</given-names></name></person-group> (<year>1995</year>). <article-title>Isotype-Specific Characterization of Antibody Responses to Onchocerca Volvulus in Putatively Immune Individuals</article-title>. <source>Parasite Immunol.</source><volume>17</volume> (<issue>7</issue>), <fpage>371</fpage>&#8211;<lpage>380</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-3024.1995.tb00904.x</pub-id><pub-id pub-id-type="pmid">8552410</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Abdel-Wahab</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1995</year>). <article-title>Onchocerca Volvulus Larval Antigen, OvB20, Induces Partial Protection in a Rodent Model of Onchocerciasis</article-title>. <source>Infect. Immun.</source><volume>63</volume> (<issue>11</issue>), <fpage>4417</fpage>&#8211;<lpage>4422</lpage>. doi: <pub-id pub-id-type="doi">10.1128/iai.63.11.4417-4422.1995</pub-id><pub-id pub-id-type="pmid">7591079</pub-id><pub-id pub-id-type="pmcid">PMC173628</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1996</year>). <article-title>Protective Immunity Induced by Vaccination With Onchocerca Volvulus Tropomyosin in Rodents</article-title>. <source>Parasite Immunol.</source><volume>18</volume> (<issue>5</issue>), <fpage>219</fpage>&#8211;<lpage>225</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-3024.1996.d01-93.x</pub-id><pub-id pub-id-type="pmid">9229374</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tchakoute</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Makepeace</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Nfon</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Njongmeta</surname><given-names>L. M.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>In a Bovine Model of Onchocerciasis, Protective Immunity Exists Naturally, Is Absent in Drug-Cured Hosts, and Is Induced by Vaccination</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>103</volume> (<issue>15</issue>), <fpage>5971</fpage>&#8211;<lpage>5976</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0601385103</pub-id><pub-id pub-id-type="pmid">16585501</pub-id><pub-id pub-id-type="pmcid">PMC1458682</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1982</year>). <article-title>Immunization of Calves Against the Microfilariae of Onchocerca Lienalis</article-title>. <source>J. Helminthol.</source><volume>56</volume> (<issue>4</issue>), <fpage>297</fpage>&#8211;<lpage>303</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0022149X00034684</pub-id><pub-id pub-id-type="pmid">7166632</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trees</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Renz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Tanya</surname><given-names>V.</given-names></name></person-group> (<year>2000</year>). <article-title>Onchocerca Ochengi Infections in Cattle as a Model for Human Onchocerciasis: Recent Developments</article-title>. <source>Parasitology</source><volume>120 Suppl</volume>, <fpage>S133</fpage>&#8211;<lpage>S142</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0031182099005788</pub-id><pub-id pub-id-type="pmid">10874716</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trpis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scoles</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Struble</surname><given-names>R. H.</given-names></name></person-group> (<year>1993</year>). <article-title>Cryopreservation of Infective Larvae of Onchocerca Volvulus (Filarioidea: Onchocercidae)</article-title>. <source>J. Parasitol.</source><volume>79</volume> (<issue>5</issue>), <fpage>695</fpage>&#8211;<lpage>700</lpage>. doi: <pub-id pub-id-type="doi">10.2307/3283607</pub-id><pub-id pub-id-type="pmid">8410541</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuji</surname><given-names>N.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kasuga-Aoki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishiwata</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>Intranasal Immunization With Recombinant Ascaris Suum 14-Kilodalton Antigen Coupled With Cholera Toxin B Subunit Induces Protective Immunity to A. Suum Infection in Mice</article-title>. <source>Infect. Immun.</source><volume>69</volume> (<issue>12</issue>), <fpage>7285</fpage>&#8211;<lpage>7292</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.69.12.7285-7292.2001</pub-id><pub-id pub-id-type="pmid">11705899</pub-id><pub-id pub-id-type="pmcid">PMC98813</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turaga</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Tierney</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Simonek</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Enyong</surname><given-names>P. A.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>Immunity to Onchocerciasis: Cells From Putatively Immune Individuals Produce Enhanced Levels of Interleukin-5, Gamma Interferon, and Granulocyte-Macrophage Colony-Stimulating Factor in Response to Onchocerca Volvulus Larval and Male Worm Antigens</article-title>. <source>Infect. Immun.</source><volume>68</volume> (<issue>4</issue>), <fpage>1905</fpage>&#8211;<lpage>1911</lpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.68.4.1905-1911.2000</pub-id><pub-id pub-id-type="pmid">10722581</pub-id><pub-id pub-id-type="pmcid">PMC97365</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Churcher</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Osei-Atweneboana</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Prichard</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Basanez</surname><given-names>M. G.</given-names></name></person-group> (<year>2013</year>). <article-title>Uncertainty Surrounding Projections of the Long-Term Impact of Ivermectin Treatment on Human Onchocerciasis</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>7</volume> (<issue>4</issue>), <elocation-id>e2169</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0002169</pub-id><pub-id pub-id-type="pmid">23634234</pub-id><pub-id pub-id-type="pmcid">PMC3636241</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Churcher</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Osei-Atweneboana</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Biritwum</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa</article-title>. <source>Clin. Infect. Dis.</source><volume>59</volume> (<issue>7</issue>), <fpage>923</fpage>&#8211;<lpage>932</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciu467</pub-id><pub-id pub-id-type="pmid">24944228</pub-id><pub-id pub-id-type="pmcid">PMC4166981</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Basanez</surname><given-names>M. G.</given-names></name></person-group> (<year>2015</year>). <article-title>Human Onchocerciasis: Modelling the Potential Long-Term Consequences of a Vaccination Programme</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>9</volume> (<issue>7</issue>), <elocation-id>e0003938</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0003938</pub-id><pub-id pub-id-type="pmid">26186715</pub-id><pub-id pub-id-type="pmcid">PMC4506122</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unnasch</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Gallin</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Soboslay</surname><given-names>P. T.</given-names></name><name name-style="western"><surname>Erttmann</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>B. M.</given-names></name></person-group> (<year>1988</year>). <article-title>Isolation and Characterization of Expression cDNA Clones Encoding Antigens of Onchocerca Volvulus Infective Larvae</article-title>. <source>J. Clin. Invest.</source><volume>82</volume> (<issue>1</issue>), <fpage>262</fpage>&#8211;<lpage>269</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI113581</pub-id><pub-id pub-id-type="pmid">2455736</pub-id><pub-id pub-id-type="pmcid">PMC303503</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>J. F.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Tromba</surname><given-names>F. G.</given-names></name></person-group> (<year>1984</year>). <article-title>An Ultraviolet-Attenuated Egg Vaccine for Swine Ascariasis: Parameters Affecting the Development of Protective Immunity</article-title>. <source>Am. J. Vet. Res.</source><volume>45</volume> (<issue>10</issue>), <fpage>2104</fpage>&#8211;<lpage>2108</lpage>.<pub-id pub-id-type="pmid">6497109</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandenberghe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chardome</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peel</surname><given-names>E.</given-names></name></person-group> (<year>1964</year>). <article-title>The Filarial Parasites of the Eastern Gorilla in the Congo</article-title>. <source>J. Helminthol.</source><volume>38</volume>, <fpage>349</fpage>&#8211;<lpage>368</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0022149X00033903</pub-id><pub-id pub-id-type="pmid">14250820</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanhamme</surname><given-names>L.</given-names></name><name name-style="western"><surname>Souopgui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghogomu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ngale Njume</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>The Functional Parasitic Worm Secretome: Mapping the Place of Onchocerca Volvulus Excretory Secretory Products</article-title>. <source>Pathogens</source><volume>9</volume> (<issue>11</issue>), <fpage>975</fpage>. doi: <pub-id pub-id-type="doi">10.3390/pathogens9110975</pub-id><pub-id pub-id-type="pmcid">PMC7709020</pub-id><pub-id pub-id-type="pmid">33238479</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Enyong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ngosso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schibel</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Moyou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tubbesing</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>1998</year>). <article-title>Onchocerca Ochengi: Epidemiological Evidence of Cross-Protection Against Onchocerca Volvulus in Man</article-title>. <source>Parasitology</source><volume>116</volume> (<issue> Pt 4</issue>), <fpage>349</fpage>&#8211;<lpage>362</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S003118209700228X</pub-id><pub-id pub-id-type="pmid">9585937</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahl</surname><given-names>G. ,. E. P.</given-names></name><name name-style="western"><surname>Schiesel</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Ngosso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tubbesing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moyou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Renz</surname><given-names>A.</given-names></name></person-group> (<year>1994</year>). <article-title>Transmission of Onchocerca Volvulus, O. Ochengi and Type D Filariae by Simulium Damnosum s.L. In North Cameroon and Its Influence on the Epidemiology of Human Onchocerciasis</article-title>. <source>Parasite</source><volume>1</volume> (<issue>1S</issue>), <fpage>S7</fpage>&#8211;<lpage>S10</lpage>.</mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Nutman</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Zea-Flores</surname><given-names>G.</given-names></name><name name-style="western"><surname>Portocarrero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lujan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ottesen</surname><given-names>E. A.</given-names></name></person-group> (<year>1988</year>). <article-title>Onchocerciasis and Immunity in Humans: Enhanced T Cell Responsiveness to Parasite Antigen in Putatively Immune Individuals</article-title>. <source>J. Infect. Dis.</source><volume>157</volume> (<issue>3</issue>), <fpage>536</fpage>&#8211;<lpage>543</lpage>. doi: <pub-id pub-id-type="doi">10.1093/infdis/157.3.536</pub-id><pub-id pub-id-type="pmid">3125261</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gazzinelli-Guimaraes</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>R. T.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Yeast-Expressed Recombinant As16 Protects Mice Against Ascaris Suum Infection Through Induction of a Th2-Skewed Immune Response</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>11</volume> (<issue>7</issue>), <elocation-id>e0005769</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0005769</pub-id><pub-id pub-id-type="pmid">28708895</pub-id><pub-id pub-id-type="pmcid">PMC5529013</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2010</year>) <source>Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/44440/9789241564090_eng.pdf?sequence=1">https://apps.who.int/iris/bitstream/handle/10665/44440/9789241564090_eng.pdf?sequence=1</uri>.<pub-id pub-id-type="pmid">21438440</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2020</year>) <source>WHO, Elimination of Human Onchocerciasis: Progress Report 2019&#8211;2020</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/who-wer9545-545-554">https://www.who.int/publications/i/item/who-wer9545-545-554</uri>.</mixed-citation></ref><ref id="B129"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group> (<year>2021</year>) <source>Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021&#8211;2030</source>. Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/9789240010352">https://www.who.int/publications/i/item/9789240010352</uri>.</mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>A. E.</given-names></name></person-group> (<year>1996</year>). <article-title>Chitinase Genes Expressed by Infective Larvae of the Filarial Nematodes, Acanthocheilonema Viteae and Onchocerca Volvulus</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>75</volume> (<issue>2</issue>), <fpage>207</fpage>&#8211;<lpage>219</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0166-6851(95)02529-4</pub-id><pub-id pub-id-type="pmid">8992319</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Egerton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pappin</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Underwood</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>The Secreted Larval Acidic Proteins (SLAPs) of Onchocerca Spp. Are Encoded by Orthologues of the Alt Gene Family of Brugia Malayi and Have Host Protective Potential</article-title>. <source>Mol. Biochem. Parasitol.</source><volume>134</volume> (<issue>2</issue>), <fpage>213</fpage>&#8211;<lpage>224</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molbiopara.2003.12.002</pub-id><pub-id pub-id-type="pmid">15003841</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>G. I.</given-names></name></person-group> (<year>1985</year>). <article-title>Brugia Malayi: Vaccination of Jirds With 60cobalt-Attenuated Infective Stage Larvae Protects Against Homologous Challenge</article-title>. <source>Am. J. Trop. Med. Hyg.</source><volume>34</volume> (<issue>6</issue>), <fpage>1132</fpage>&#8211;<lpage>1137</lpage>. doi: <pub-id pub-id-type="doi">10.4269/ajtmh.1985.34.1132</pub-id><pub-id pub-id-type="pmid">3834797</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yutanawiboonchai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Brigandi</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Rotman</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name></person-group> (<year>1996</year>). <article-title>Structural and Molecular Specificity of Antibody Responses in Mice Immune to Third Stage Larvae of Onchocerca Volvulus</article-title>. <source>Parasite Immunol.</source><volume>18</volume> (<issue>2</issue>), <fpage>95</fpage>&#8211;<lpage>102</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-3024.1996.d01-51.x</pub-id><pub-id pub-id-type="pmid">9223162</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Tricoche</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>L. Y.</given-names></name><name name-style="western"><surname>Asojo</surname><given-names>O. A.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Ligand Binding Properties of Two Brugia Malayi Fatty Acid and Retinol (FAR) Binding Proteins and Their Vaccine Efficacies Against Challenge Infection in Gerbils</article-title>. <source>PloS Negl. Trop. Dis.</source><volume>12</volume> (<issue>10</issue>), <elocation-id>e0006772</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0006772</pub-id><pub-id pub-id-type="pmid">30296268</pub-id><pub-id pub-id-type="pmcid">PMC6193737</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loukas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hawdon</surname><given-names>J. M.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Ac-SAA-1, an Immunodominant 16 kDa Surface-Associated Antigen of Infective Larvae and Adults of Ancylostoma Caninum</article-title>. <source>Int. J. Parasitol.</source><volume>34</volume> (<issue>9</issue>), <fpage>1037</fpage>&#8211;<lpage>1045</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijpara.2004.04.015</pub-id><pub-id pub-id-type="pmid">15313130</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>